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1. Introduction 
1.1 Macroscopic structure of the heart  
A normal human heart is an organ with four chambers. The upper chambers, the right 
and left atria, receive incoming blood. The left atrium receives oxygenated blood from 
the pulmonary circulation and the right atrium receives blood from the systemic 
circulation. The lower chambers, the more muscular right and left ventricles, pump 
blood out of the heart into the lungs and into the main circulation (Guyton and Hall, 
2006).  
 
1.2 Cardiac function and dysfunction 
The heart services as a pump of the circulation, to transport nutrients and oxygen to 
the body tissues, to transport metabolic waste products away from the tissues, to 
conduct hormones through different parts of the body, and, in general, to maintain an 
appropriate environment in all the tissue fluids of the body for optimal survival and 
function of the cells (Guyton and Hall, 2006).  
A reduction or damage of cardiac function could cause systemic complications. In 
adults with congenital heart disease, nearly all organ systems were reported to be 
affected (Lui et al., 2017), including decreased glomerular filtration rate (GFR) 
(Dimopoulos et al., 2008), a reduced forced vital capacity positively related to the 
complexity of the underlying heart defect in pulmonary function tests 
(Alonso-Gonzalez et al., 2013) and other organ dysfunctions (Alonso-Gonzalez et al., 
2013, Fredriksen et al., 2001).  
Kidney disease is commonly found in heart failure (HF) patients (Grande et al., 2017). 
It was found that GFR is associated with the degree of cardiac 
diastolic dysfunction and adverse clinical outcomes (Jain et al., 2017). A recent 
nationwide population-based cohort study showed that heart failure patients have a 
higher risk of developing dementia (Adelborg et al., 2017). Studies also revealed 
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altered cerebral hemodynamics in heart failure. Reduced cerebral blood flow velocity 
and regional cerebral oxygen saturation was observed in HF patients (Mamalyga and 
Mamalyga, 2017, Erkelens et al., 2017).  
 
1.3 Assessment of cardiac function 
In 1962, Folse and Braunwald published their study about the use of a radioisotope 
indicator dilution technique to assess the ‘fraction of left ventricular volume ejected 
per beat’ (Folse and Braunwald, 1962). This first description of a technique to 
measure what has subsequently been coined ‘ejection fraction’ heralded an era in 
which this single measure has become the most important metric of cardiac function 
utilized by clinicians (Cikes and Solomon, 2016). Factors such as exercise, diabetes, 
and hypertension have been reported to correlate with left ventricular ejection fraction 
(LVEF) (Haddadzadeh et al., 2011, Ehl et al., 2011, Georgiopoulou et al., 2013). The 
2013 ACCF/AHA guidelines classify heart failure (HF) as a complex clinical 
syndrome that results from any structural or functional impairment of ventricular 
filling or ejection of blood. HF patients with a LVEF of ≥50% were defined as having 
a preserved ejection fraction (HFpEF) (Yancy et al., 2013). Numerous studies suggest 
that a LVEF of <50% is associated with the development of heart failure (Fonarow 
and Hsu, 2016) and a LVEF less than 35% might be indicative of manifest heart 
failure.  
Besides LVEF, there are several parameters that contribute to the assessment of 
cardiac function. Left ventricular (LV) geometry and left atrium size is independently 
associated with morbidity and mortality in patients with HFpEF (Zile et al., 2011).  
Increased baseline LV mass and abnormal LV geometry portend an increased risk for 
morbidity and mortality following high-risk myocardial infarction (Verma et al., 
2008).  
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1.4 Cellular composition of the heart 
The cell is the basic structural and functional unit of an organ. Proper cell function is 
essential for maintaining homeostasis. An accurate and up to date knowledge of 
cardiac cellular composition is needed to better understand normal cardiac function as 
well as the complex pathogenesis of cardiac disease processes.  
A recent study from Pinto et al. (Pinto et al., 2016) analysed cellular composition in 
adult mouse and human hearts by using a combination of genetic tools and cellular 
markers. Immunohistochemistry revealed 31.0 ± 4.2% of nuclei can be attributed to 
cardiomyocytes, 43.6 ± 4.1% to endothelial cells (ECs), 4.7 ± 1.5% to leukocytes and 
unmarked cells accounted for 20.7 ± 4.5% of the nuclei in the adult mouse heart. 
Afterwards, examination of human tissues demonstrated that 31.2 ± 5.6% of nuclei 
correspond to cardiomyocytes, 53.8 ± 6.4% to ECs, and 2.8 ± 1.2% to leukocytes. 
Further detection of non-myocytes in adult mouse hearts delineated a distribution 
consisting of 64% ECs, 27% resident mesenchymal cells (15% fibroblasts plus 12% 
others), and 9% leukocytes (7% myeloid plus others). Immunofluorescence detection 
in murine cardiac tissue further indicated the presence of 5.7±1.1% vascular smooth 
muscle cells (VSMCs) and/or pericytes, which account for a major part of the 
unmarked cells in the other staining. Current estimation of EC abundance in the 
human heart reflects those observed in the mouse heart.  
Cardiac cellular plasticity has been extensively studied during the last decade. In a 
study by Bergmann et al. in 2015 (Bergmann et al., 2015), it was determined 
post-mortem that 73.6% ± 7.0% of all cardiomyocytes were mono-nucleated, 25.5% ± 
7.4% were bi-nucleated, and 1.0% ± 1.2% were tri-nucleated in the heart of 
individuals aged one month to 73 years. In agreement with previous studies (Mollova 
et al., 2013, Olivetti et al., 1996), they established that already 1 month after birth; the 
final number of cardiomyocytes was reached (3.2 ± 0.75 × 10
9
 cells) and remained 
constant throughout life. By stereological measuring the average volume of 
cardiomyocytes at different ages, it was found that the adaptive about 3-fold greater 
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growth of the left ventricle can be fully explained by the increase in volume of the 
cardiomyocytes. Moreover, it was shown that cardiac endothelial and mesenchymal 
cells also expand during physiological growth of the heart.   
 
1.5 The vascular system 
1.5.1 Macrovascular and microvascular endothelial cells 
Endothelial cells form a cell monolayer which lines the entire vascular system, from 
the heart to the smallest capillary. Arteries and veins have a thick wall composed 
of connective tissue and, at least in arteries, of many layers of smooth muscle cells 
that constitute the so-called media. The innermost wall, designated intima, is lined by 
an exceedingly thin monolayer of ECs, known as macrovascular endothelial 
cells, separated from the surrounding medial layers by a basal lamina. In the finest 
branches of the vascular tree, the capillaries, the vessel wall consist of nothing but 
ECs and a basal lamina. These ECs are known as microvascular endothelial cells 
(Bruce et al., 2002).  
 
1.5.2 Endothelial cell heterogeneity 
The vascular endothelium is an essential locus of regulatory nodes in the homeostatic 
network to achieve diverse organ functions (Gimbrone, 1987). In consideration of 
achieving precise regulation of various functions, heterogeneity among endothelial 
cells has been extensively investigated.  
In general, from a structural point of view, the shape of endothelial cells varies across 
the vascular tree (Aird, 2007). Thus, endothelial cell thicknesses varies from less than 
0.1 μm in capillaries and veins to 1 μm in the aorta (Florey, 1966). The endothelium 
of arteries and veins forms a continuous uninterrupted layer of cells, held together by 
tight junctions. The endothelium of capillaries may be continuous, fenestrated, or 
discontinuous, according to the needs of the underlying tissue (Aird, 2012). Besides 
Introduction 
8 
 
such differences at the structural level, ECs show remarkable heterogeneity in 
function. For example, phosphorylation and movement of adherence junction protein 
VE-cadherin altered endothelium permeability (Su et al., 2002, Semina et al., 2014). 
And VE-cadherin was found differently expressed on venous, capillary and arterial 
endothelial cells (Herwig et al., 2008). Moreover, it was observed (Moldobaeva and 
Wagner, 2002) that bradykinin caused a maximal increase in permeability in sheep 
bronchial artery and bronchial microvascular endothelial cells, while thrombin 
treatment was able to enhance permeability only in microvascular ECs. For studies 
about endothelial cell function in a particular organ, organ-specific heterogeneity of 
ECs would be highly interesting.  
 
1.5.3 Endothelial cell activation and dysfunction 
The term endothelial activation was first coined in the 1960s. Willms-Kretschmer 
(Willms-Kretschmer et al., 1967) used ‘activated’ to imply a change of endothelial 
cell function as well as morphology observed during experiments. Afterwards, 
numerous studies have shown surface molecule expression change and altered 
functions in endothelial cells upon cytokine stimulation. In the 1990s, the term 
endothelial cell activation was reintroduced to emphasize that such changes do not 
reflect endothelial cell injury or dysfunction (Hunt and Jurd, 1998).  
Endothelial dysfunction is a pathological condition characterized mainly by an 
imbalance between mediators with vasodilating, anti-mitogenic, and anti-thrombotic 
properties (endothelium-derived relaxing factors) and substances with 
vasoconstricting, pro-thrombotic, and growth-promoting characteristics 
(endothelium-derived contracting factors) (Flammer et al., 2012). Furchgott and 
Zawadzki (Furchgott and Zawadzki, 1980) first described the phenomenon of 
endothelium-dependent relaxation in 1980. Subsequently, the identification of nitric 
oxide (NO) as the crucial endothelium-derived mediator of vascular relaxation led to 
substantial progress in cardiovascular research (Flammer et al., 2012). In addition to 
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causing vascular smooth muscle cell (SMC) relaxation, NO is known to selectively 
reduce endothelial cell expression of adhesion molecules and pro-inflammatory 
chemokines or cytokines (De Caterina et al., 1995). 
Since endothelial cell activation proceeding to endothelial dysfunction was commonly 
observed, endothelial activation / dysfunction has been studied as two converging 
concepts. The influence and regulation of endothelial activation / dysfunction has 
been strongly correlated with the pathogenesis of complex disease processes such as 
diabetes (Jia et al., 2017, Watt et al., 2017), maladaptive cardiac remodelling (Rose et 
al., 2017, Tsai et al., 2017), and atherosclerosis (Corban et al., 2017).   
 
1.5.4 Cardiac endothelium 
The endocardium consists of a continuous endothelial cell monolayer lining the inner 
wall of the cavities of the heart; therefore they have been termed endocardial 
endothelial cells and present an organ-specific subtype of macrovascular ECs. The 
inner surface of the conduit coronary arteries and veins as well as that of the 
resistance-sized arterioles is covered by a different type of macrovascular ECs while 
the capillaries and post-capillary venules are lined by a continuous monolayer of 
microvascular ECs (Noireaud and Andriantsitohaina, 2014). The small coronary 
arteries and arterioles are able to match blood flow and thus delivery of oxygen and 
nutrients to the myocardium according to its demand by adapting their tone and thus 
resistance to blood flow (coronary reserve). This ‘auto regulation’ may be severely 
compromised by coronary heart disease, i.e. atherosclerosis in the large conduit 
arteries preceding the resistance vessels, eventually leading to ischemia of the 
myocardium. It is the capillaries where oxygen, nutrients and other mediators are 
exchanged between the blood and the interstitium. Figure 1A shows a cross-section 
image from an adult mouse myocardium. It clearly delineates that there is at least one 
capillary next to each cardiomyocyte. This anatomical arrangement of cardiomyocytes 
within the capillary network not only allows for the exchange of nutrients and 
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metabolites but also for a rather intimate bidirectional communication between 
endothelial cells and cardiomyocytes (Hsieh et al., 2006)  
 
Figure 1. Microvascular endothelial cells in the heart. A. Endothelial cell-cardiomyocyte 
assembly in an adult mouse myocardium. Cardiomyocyte cell borders are stained in red, 
capillary EC borders in green (isolectin-fluorescein staining) and nuclei in blue (Hoechst dye). 
Original magnification: 600 (Hsieh et al., 2006). B. Endothelial cells interact with cardiac 
myocytes and fibroblasts though multiple ways (adapted from (Howard and Baudino, 2014)). 
As delineated in Figure 1B, it is well-known that capillary ECs interact with nearby 
cardiomyocytes and fibroblasts thought multiple ways. Cardiomyocytes and 
endothelial cells communicate through gap junction proteins, such as Cx43, which 
link electromechanical processes in the myocardium with the vasculature (Givvimani 
et al., 2011). The endothelial cell secretory products comprising growth factors, 
cytokines, NO, endothelin-1, and neuregulin act on myocytes and fibroblasts in a 
paracrine manner (Takeda and Manabe, 2011, Penna et al., 2017). A recent study 
showed that NO produced by coronary endothelial cells plays a pivotal role in the 
cardioprotective effect of exercise (Farah et al., 2017). Moreover, endothelial 
cell-derived neuregulin protects cardiomyocytes against hypoxia-reoxygenation 
induced apoptosis and reduces infarct sizes after coronary artery ligation (Hedhli et 
al., 2011). 
The extracellular matrix (ECM) acts as a scaffold for the heart and allows for cellular 
and acellular networks to form in the heart. It contains molecules released from 
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cardiomyocytes and non-myocytes, especially matrix metalloproteinases (MMPs) and 
tissue inhibitors of metalloproteinases (TIMPs), which correlate with endothelial cell 
proliferation, increased tube formation, and lead to changes in angiogenesis (Liu et 
al., 2008, Shen et al., 2016).  
 
1.6 Cardiac hypertrophy and heart failure 
1.6.1 A brief macroscopic view of the process of cardiac hypertrophy 
Cardiac hypertrophy is except in endurance sports (Radovits et al., 2013) a 
maladaptive response of the heart to a variety of extrinsic and intrinsic stimuli. 
Extrinsic stimuli comprise, e.g. arterial hypertension (Frohlich et al., 1992) or aortic 
valve stenosis, while familial hypertrophic cardiomyopathy (Marian and Braunwald, 
2017) is prototypic for intrinsic stimuli. The critical point during both maladaptive 
remodelling processes is the biomechanical overload to which the heart is chronically 
exposed (Frey and Olson, 2003). 
 
Figure 2. Development and progression of cardiac hypertrophy. A. The progression from 
a normal heart to ‘compensated’ hypertrophy, which per se is a maladaptive process (e.g. 
decreased fractional shortening as the first sign of a systolic dysfunction), manifests itself as 
cardiomyocyte growth together with an increase in thickness of the (left) ventricular wall 
(w' > w, wall thickness) to normalize wall tension. B. The progression from this intermediate 
state to decompensated hypertrophy (heart failure) is accompanied by a major remodelling 
process within the ECM that ultimately causes increased cardiomyocyte apoptosis and 
necrosis provoking the transition to dilated cardiomyopathy (r'' > r', radius of the ventricular 
cavity) and wall thinning (w'' < w') hence a major increase in wall tension. Adapted from 
(Diwan and Dorn, 2007). 
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As delineated in Figure 2, in the face of hemodynamic stress or ischemic injury, 
cardiomyocytes respond with enhanced protein synthesis, heightened organization of 
the sarcomeres, increased transcriptional activity such as an upregulation of the 
calcineurin-nuclear factor of activated T-cells (NFAT) pathway, re-expression of fetal 
genes such as atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and 
β-myosin heavy chain (β-MHC), and manifests itself by increased cardiomyocyte size, 
ventricular wall thickness and neurohormonal activation. These changes have 
previously been considered as an adaptive response to maintain cardiac output. In fact, 
they already lead to systolic dysfunction of the heart because of the compromised 
slower contraction of the enlarged cardiomyocytes. Moreover, there is an activation of 
the cardiac fibroblasts which start to remodel the ECM by replacing the normal 
collagen skeleton with other collagens that are much less tear-resistant. If the 
inadequate hemodynamic stress persists, the remodelling process ultimately leads to 
enhanced cardiomyocyte death, increased fibrosis, dilatation of the ventricle and thus 
a major increase in wall tension that can no longer be compensated (critical heart 
weight has been reached) so that cardiac output drops below the critical level. In fact, 
dilated cardiomyopathy, the end-stage of this maladaptive remodelling process, is by 
far the main reason for affected individuals to develop heart failure (Diwan and Dorn, 
2007, Frey and Olson, 2003).    
In earlier clinical trials (Hood et al., 1968, Grossman et al., 1975), it was observed 
that pressure overload of the left heart was exactly counterbalanced by increased wall 
thickness in the left ventricle. Subsequent studies have shown that this left ventricular 
hypertrophy is associated with a significantly increased risk of clinical events, such as 
an enhanced incidence of coronary heart disease as well as increased mortality from 
cardiovascular disease (Levy et al., 1990, Koren et al., 1991). Some clinical trials 
further demonstrated that patients with arterial hypertension and 
echocardiographically documented left ventricular hypertrophy, who received either 
the AT1 receptor blocker losartan or the β1 receptor blocker atenolol, were much less 
likely to experience such a major cardiovascular event (Kjeldsen et al., 2002). Also 
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the angiotensin-converting-enzyme inhibitor ramipril significantly reduces the rates of 
death, myocardial infarction, and stroke in a broad range of high-risk patients (Heart 
Outcomes Prevention Evaluation Study et al., 2000). It was proposed during the last 
decade and is meanwhile widely accepted that the development of cardiac 
hypertrophy should be prevented in patients with pressure overload (Frey et al., 2004). 
Since then numerous studies have been undertaken to delineate the cellular 
mechanisms that spur cardiac hypertrophy. With the improved understanding of the 
process in recent years there has been a controversy about whether inhibition of the 
development of ventricular hypertrophy is a proper therapeutic strategy in patients 
with ventricular pressure overload (Schiattarella and Hill, 2015, Crozatier and 
Ventura-Clapier, 2015). 
 
1.6.2 Potential circulating biomarkers during cardiac hypertrophy 
- Endothelin-1 (ET-1) 
Endothelin-1 (ET-1) was discovered in 1980 as an endothelial cell-derived peptide 
with great vasoconstrictive potency. It has been shown that ET-1 achieves its effects 
through two receptors: the ETA receptor, mainly located on vascular smooth muscle 
cells and on cardiomyocytes; and the ETB receptor, mainly located on vascular 
endothelial cells (Farhat et al., 2008, Sanchez et al., 2002, Brunner et al., 2006).  
Stimulation by ET-1 has been shown to induce cardiac hypertrophy both in vitro (Jen 
et al., 2017) and in vivo (Archer et al., 2017). High levels of plasma big endothelin-1, 
the biological precursor of endothelin-1, were observed to predict a worse prognosis 
for patients with hypertrophic cardiomyopathy (Wang et al., 2017b). In a recent trial 
(Demissei et al., 2017) aiming at predicting low risk vs. high risk for early 
post-discharge death or  for readmission to hospital of  HF patients due to 
acute heart failure, ET-1 plasma levels showed better performance for high-risk 
prediction than other biomarkers. 
 
- Atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) 
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Atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) are myocardial 
cell-derived peptides, the release of which is enhanced in response to hypervolemia in 
the atria or pressure overload in the ventricles, with similar structure but different 
actions on cardiorenal and fluid homeostasis (Torres-Courchoud and Chen, 2016). 
ANP is released mainly from the atria in the normal heart, but major amounts were 
found in ventricles of fetuses and in patients with left ventricular hypertrophy 
(Federico, 2010). Moreover, the plasma concentration of ANP is elevated in essential 
hypertension (Kato et al., 1999, Hu et al., 2015), and has been observed to correlated 
with higher renin activity in some cases, which was further indicated to have a 
counterregulatory role during activation of the renin-angiotensin-aldosterone system 
(Sergev et al., 1991). Higher plasma concentration of ANP was also found 
companioned with more frequent premature ventricular depolarizations, and more 
advanced hemodynamic abnormalities in patients with chronic heart failure (Gottlieb 
et al., 1989). 
Increased wall tension normally drives synthesis of pre–proBNP in the atrial and 
ventricular myocardium. Subsequently, the pre-propeptide is cleaved first to 
proBNP1–108, then to the biologically active BNP1–32 and the inactive 
amino-terminal fragment (NT-proBNP) (Chen and Burnett, 1999). During cardiac 
hypertrophy, plasma BNP concentration is a sensitive marker for moderate-to-severe 
preclinical systolic dysfunction, but less so for milder systolic dysfunction or diastolic 
dysfunction (Redfield et al., 2004). It was observed that both BNP and NT-proBNP 
plasma levels are significantly higher in HF patients compared with healthy subjects, 
whereby NT-proBNP levels are more sensitive and specific to distinguish HF from 
non-HF subjects (Fonseca et al., 2004). NT-proBNP levels were also suggested to be 
highly predictive of incident atrial fibrillation, the most common cardiac rhythm 
abnormality, after adjustment for an extensive number of covariates (Patton et al., 
2009).  
Although ANP and BNP have been recommended to provide prognostic information 
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during the process of cardiovascular diseases, the release of these peptides may 
considerably influence pathogenesis of the underlying disease processes. Enhanced 
early endogenous natriuretic peptide activation partly contributes to post-ischemic 
cardioprotection due to their pro-angiogenic, anti-apoptotic, anti-hypertrophic and 
anti-fibrotic effects (Lilyanna et al., 2015).  ANP also attenuated myocardial 
fibrosis and inflammation in angiotensin II-induced cardiac remodelling in mice 
(Fujita et al., 2013). However, there is a study which showed that in mice with dilated 
cardiomyopathy, cardiac-targeted over-expression of corin, an enzyme that cleaves 
natriuretic peptides, significantly reduces the development of cardiac fibrosis and 
enhances cardiac contractile function (Gladysheva et al., 2013). In consideration of 
the complex disease progresses, the various roles that ANP and BNP play in 
cardiovascular disease motivate further investigation in this area of research. 
 
1.7 Cardiac endothelium and cardiac hypertrophy 
1.7.1 Angiogenesis and cardiac hypertrophy 
During the process of cardiac hypertrophy, along with the growth of cardiomyocytes 
and enhanced contractility, interstitial cells, such as capillary endothelial cells and 
cardiac fibroblasts, also dynamically undergo a phenotypic change. While the 
cardiomyocytes grow in proportion to the increase in heart mass, the capillary 
network does not expand to the same extent and eventually becomes limiting for 
oxygen and nutrients supply to the cardiomyocytes when the so-called critical heart 
weight is reached (Oka et al., 2014). There is evidence that cardiac angiogenesis is 
enhanced during the acute phase of adaptive cardiac growth (e.g., in endurance 
athletes) but reduced as hearts undergo pathological remodelling. Enhanced 
angiogenesis in adaptive remodelling was associated with myocardial VEGF and 
angiopoietin-2 release, whereas inhibition of VEGF in maladaptive remodelling led to 
decreased capillary density and impaired cardiac function (Shiojima et al., 2005, Rose 
et al., 2017). NO production also plays a critical role in the mechanism that couples 
cardiac angiogenesis to cardiomyocyte growth. Enhancing endothelial cell release of 
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NO induced an increase in cardiomyocyte size and left ventricular wall thickness by 
promoting proteasomal degradation of the regulator of G-protein signalling type 4, 
RGS-4 (Jaba et al., 2013).  
 
1.7.2 Endothelial cell – cardiomyocyte interaction during the process of cardiac 
hypertrophy 
As delineated in Figure 2, endothelial cells communicate with cardiomyocytes and 
other interstitial cells through multiple channels. E-selectin, intercellular adhesion 
molecule-1 (ICAM-1) and NADPH oxidase 2 expression in cardiac ECs is 
upregulated in HFpEF patients as compared to healthy subjects, suggesting that 
HFpEF is associated with coronary microvascular endothelial cell activation and 
oxidative stress (Franssen et al., 2016). Cardiac fibrosis is known to contribute largely 
to the transition of ‘compensated’ cardiac hypertrophy to heart failure. 
Endothelial-to-mesenchymal transition contributes to the process of cardiac fibrosis 
(Zeisberg et al., 2007). Human cardiac endothelial cells abundantly express bone 
marrow kinase in chromosome X (Bmx), an arterial non-receptor tyrosine kinase, 
while very little Bmx is expressed by cardiomyocytes. Angiotensin II (Ang 
II)-induced cardiac hypertrophy is significantly reduced in mice deficient in Bmx, so 
that there may be a cross-talk between endothelial cells and cardiomyocytes through 
Bmx activity during of cardiac remodelling (Holopainen et al., 2015).   
 
1.8 Aims of the study 
Previous studies have demonstrated an essential role of the cardiac endothelium, 
namely the vascular ECs, in maintaining proper cardiac function and to prevent 
pathological remodelling processes underlying cardiac disease. ANP and BNP are 
crucial peptide mediators released by the myocardium with a variety of functions 
throughout the cardiovascular system. Despite a multitude of studies on endothelial 
cell – cardiomyocyte interaction in the heart, very little is known about the influence 
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of endothelial cells on ANP and BNP expression by cardiomyocytes.  
Myocardial endothelial cell activation influences cardiomyocyte size and contractility, 
and thus plays an important role in the progression of cardiac hypertrophy. The 
cellular mechanism underlying this effect has been widely investigated, but has not 
been uncovered yet. Endothelin-1 is a circulating vasoactive peptide known to induce 
endothelial cell activation and dysfunction. Plasma ET-1 levels are elevated in 
patients with arterial hypertension and cardiac hypertrophy. We therefore wondered 
which effect ET-1 activation of endothelial cells may have on cardiomyocyte ANP 
and BNP expression in a novel EC-cardiomyocyte interaction model in vitro. 
The aims and strategies of this work can be summarized as follows: 
1. Basic characterization of the microvascular endothelial cells used in this study.  
2. To establish an endothelial cell – cardiomyocyte co-culture system in vitro. 
3. To analyse ANP and BNP expression in cardiomyocytes co-cultured with 
endothelial cells (with and without ET-1 activation). 
4. To characterize the nature of this cross-talk between the two cells, whether this 
requires physical cell-cell contact or is mediated by a humoral EC-derived factor, 
and to characterize this(these) factor(s) by employing MALDI-TOF mass 
spectrometry analysis. 
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2. Materials  
2.1 Consumables 
Tab. 1: Consumables 
Material Supplier 
Biosphere
®
 SafeSeal tubes Sarstedt 
Cell culture flasks (T-25, T-75) Sarstedt 
Cell culture pipettes and tips  Sarstedt 
Cell culture plates and dishes Sarstedt 
Cell scrapers Sarstedt 
Falcon
®
 cell culture insert companion plates Corning 
Falcon
®
 cell culture inserts (0.4 μm) Corning 
Glass cover slides Marienfeld 
Immobilon
®
-P PVDF membrane (0.45 μm) Merck Millipore 
Microscope slides Marienfeld 
PCR LightCycler
®
 capillaries Roche 
Vivaspin
®
 6 centrifugal concentrators  Sartorius 
 
2.2 Cell culture medium and supplements 
Tab. 2: Cell culture medium and supplements 
Material Supplier 
Claycomb medium Sigma-Aldrich 
DMEM medium 
(1g/ml glucose; 4.5g/ml glucose) 
Gibco, Life Technologies 
D-PBS Gibco, Life Technologies 
ECGS PromoCell 
Fetal bovine serum (FCS) for ECs Gibco, Life Technologies 
Fetal bovine serum (FCS) for HL-1 cells Sigma-Aldrich 
Fungizone Gibco, Life Technologies 
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Gelatin Merck 
HEPES Sigma-Aldrich 
L-Glutamine Sigma-Aldrich 
Na-Pyruvate Gibco, Life Technologies 
Non-Essential-Amino-Acids Gibco, Life Technologies 
Norepinephrine Sigma-Aldrich 
Penicillin/Streptomycin Gibco, Life Technologies 
Trypsin-EDTA Gibco, Life Technologies 
 
2.3 Chemicals and reagents 
Tab. 3: Chemicals and reagents 
Chemical/Reagent Supplier 
Acrylamid (30%)  Merck 
Agarose Sigma-Aldrich 
Angiopoietin-2 (mouse, recombinant) R&D system 
Bovine Serum Albumin Sigma-Aldrich 
β- Mercaptoethanol  Sigma-Aldrich 
DCF (CM-H2DCFDA) Invitrogen 
DMSO Sigma-Aldrich 
Dithiothreitol (DTT) Sigma-Aldrich 
Endothelin-1 (human, procine) Sigma-Aldrich 
Ethanol (99%) Sigma-Aldrich 
FK506  Enzo Life Sciences 
Fluoroshield™ with DAPI Sigma Aldrich 
Glucose Merck 
IFN-gamma (murine, recombinant) Gibco, Life Technologies 
Luminata™ Western HRP Chemiluminescence  Merck Millipore 
L-Glutamine Sigma-Aldrich 
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Naphthylendiamin Sigma-Aldrich 
Paraformaldehyde (PFA) Thermo Scientific  
Pefabloc Sigma-Aldrich 
Protein-assay-concentrate   Bio-Rad 
Sodium dodecyl sulfate (SDS) SERVA Electrophoresis  
Sodium chloride Sigma-Aldrich 
Sulfanilamide Sigma-Aldrich 
TNF-alpha (murine, recombinant) Gibco, Life Technologies 
TEMED Carl Roth 
Tween
®
 20 Carl Roth 
Triton-X 100 Sigma-Aldrich 
 
2.4 Buffer solutions 
Tab. 4: Buffer solutions 
Buffer Composition  
Phosphate-buffered saline (PBS)  
(per liter) 
NaCl 
KCl 
Na2HPO4 
 
8.0 g 
0.2 g 
1.44 g 
 
Tris-buffered saline (TBS) 
(per liter) 
Tris (0.5 M) 
NaCl (1.5 M) 
 
6.1 g 
8.75 g 
PBS-T/TBS-T 0.5 ml Tween
®
 20 in 1 L 1×PBS/TBS 
 
Homo-Ⅰbuffer (2×) Tris 
KCl 
EDTA 
Glucose 
50 mM 
1.15% 
2 mM 
5 mM 
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Homo buffer  Homo-Ⅰbuffer (2×)                    
Dithiothreitol (0.1 M)                
Pefabloc (40 mg/ml)                    
Protease inhibitor mix              
 
485 μl 
1 μl 
2 μl 
12 μl 
Protease inhibitor mix (PIM) 
 
Pepstatin A 
Hepes (15 mM) 
Leupeptin 
Hepes (15 mM) 
 
1 mg in 200 μl DMSO 
800 μl 
1 mg in 200 μl DMSO 
800 μl 
Western blot (WB) 
-Running buffer (10×) 
Tris 
Glycine 
SDS 
H2O 
 
248 mM 
1.92 M 
35 mM 
WB-Transfer buffer (10×) Tris 
Glycine 
H2O 
 
248 mM 
1.92 M 
 
 
WB-blocking buffer 5% Milk powder in TBST 
 
WB-Stripping buffer NaOH 0.2 M 
 
2.5 Kits 
Tab. 5: Kits 
Kit Supplier 
RNeasy
®
 RNA extraction Kit Qiagen 
Omniscript
®
 Reverse Transcription Kit Qiagen 
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QuantiTect
®
 SYBR
®
 Green PCR Kit Qiagen 
ANP ELISA Kit Sigma-Aldrich 
VEGF-C ELISA Kit  Aviva System Biology 
 
2.6 PCR Primers 
Tab. 6: PCR primers 
Gene 
(Murine) 
Sequence Supplier Tannealing 
ICAM-1 For 5’-ATCTCAGGCCGCAAGGG-3’ 
Rev 5’-CGAAAGTCCGGAGGCTGG-3’ 
 
Biomers 60℃ 
VCAM-1 For 5’-CCCCAAGGATCCAGAGATTCA-3’ 
Rev 5’-ACTTGACCGTGACCGGCTT-3’ 
 
Biomers 60℃ 
ANP Proprietary 
QuantiTect Primer Assay Mm_LOC230899_1_SG 
 
Qiagen 
 
55℃ 
BNP Proprietary 
QuantiTect Primer Assay Mm_Nppb_1_SG  
 
Qiagen 55℃ 
β-MHC Proprietary 
QuantiTect Primer Assay Mm_Myh7_1_SG 
 
Qiagen 55℃ 
RPL32  For 5’-GGGAGCAACAAGAAAACCAA-3’ 
Rev 5’-ATTGTGGACCAGGAACTTGC-3’ 
 
Biomers 55℃ 
NOS3 
 
For 5’-CCTTCCGCTACCAGCCAGA-3’ 
Rev 5’-CAGAGATCTTCACTGCATTGGCTA-3’ 
Biomers 55℃ 
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MCP-1 For 5’-CCAGCCGGCAACTGTGA-3’ 
Rev 5’-CCAGCCGGCAACTGTGA-3’ 
 
Biomers 60℃ 
VEGFR2 For 5’-TAGCTGTCGCTCTGTGGTTCT-3’ 
Rev 5’-TGTCAGTATGTCTTTCTGTGTGCT-3’ 
 
Biomers 58℃ 
VEGFR3 For 5’-AACTCTCCAGCATCCTGACCATC-3’ 
Rev 5’-AGCCACTCGACACTGATGAAGG-3’ 
 
Biomers 58℃ 
VEGF-C Proprietary 
QuantiTect Primer Assay Mm_Vegfc_1_SG 
Qiagen 58℃ 
 
2.7 Antibodies 
Tab. 7: Antibodies 
Primary-Antibody Supplier Working dilution 
Mouse monoclonal anti-NOS3 BD Biosciences  1:1000 WB 
Rabbit monoclonal anti-VACM-1 Novus Biologicals 1:1000 WB 
Mouse monoclonal anti-β-actin Abcam 1:5000 WB 
Mouse monoclonal anti-Ang2 R&D System 1:1000 WB;  1:400 ICC 
Rabbit polyclonal anti-vWF 
 
Santa Cruz 
Biotechnology 
1:400 ICC 
WB: Western Blot; ICC: Immunocytochemistry 
 
Secondary-Antibody Supplier Working dilution 
Goat anti Mouse IgG HRP Rockland Immunochemicals 1:5000 WB 
Goat anti Rabbit IgG HRP Rockland Immunochemicals 1:5000 WB 
Goat anti rabbit Alexa 488 LuBioScience 1:200 ICC 
Donkey anti mouse Alexa 568 LuBioScience 1:200 ICC 
WB: Western Blot; ICC: Immunocytochemistry 
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2.8 Equipment 
Tab. 8: Equipment 
Equipment Supplier 
Cell culture CO2 incubator Nuaire 
Centrifuge Eppendorf 
Cone-and-plate viscometer Martin-Luther University, 
Halle-Wittenberg 
Dmi1-Light microscope Leica 
Fluorescence spectrophotometry Thermo Fisher Scientific  
Freezer (-20℃) Liebherr 
Freezer (-80℃) Sanyo 
Fridge (4℃) Liebherr 
ImageQuant™ LAS 4000 mini Image system  GE Healthcare 
Laminar airflow workstation Nuaire 
LightCycle
®
 1.5 q-RT-PCR system Roche 
Mini-Protean
®
 electrophoresis system  Bio-Rad 
NanoDrop
®
 ND-1000 spectrophotometer Thermo Fisher Scientific 
PowerWave™ XS microplate spectrophotometer Bio-Tek 
TCS SP8 confocal microscope Leica 
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3. Methods 
3.1 Cell culture 
3.1.1 Endothelial cells, cardiomyocytes cell culture 
The mouse cardiac endothelial cell (MCEC) line was prepared from microvascular 
neonatal mouse cardiac endothelial cells by transfection with lentiviral vectors 
carrying SV40T antigen and human telomerase. This cell line was provided by 
Cedarlane
®
, US. Functionally immortalized murine microvascular endothelial cells 
(CI-muMECs) were provided by InSCREENeX, Germany, with proprietary 
technology. 
MCECs were maintained in DMEM cell culture medium (1g/ml glucose) with 5% 
FCS and 1% penicillin/streptomycin. CI-muMECs were maintained in DMEM cell 
culture medium (5 g/ml glucose) with 20% FCS, 1% penicillin/streptomycin, 0.5% 
ECGS, 0.02% Fungizone, 1% Na-pyruvate and 1% non-essential-amino-acids. Both 
cell lines were seeded on 2% gelatin coated surface, kept at 37 °C, with 5% CO2 and 
appropriate humidity.   
A cardiac muscle cell line, HL-1, was derived from the AT-1 mouse atrial 
cardiomyocyte tumor lineage by Claycomb WC et al., and kindly provided. HL-1 
cells were seeded on 2% gelatin/fibronectin coated surfaces. Cells were maintained in 
Claycomb medium supplied with 10% FBS, 1% penicillin/streptomycin, 1% 
norepinephrine and 1% L-glutamine.  
Cells were split into sub-cultures at a ratio of 1:3-1:5 at around 90% confluence, by 
trypsin-EDTA (0.05%) gentle digestion. Cell culture medium was refreshed every 2-3 
days.    
 
3.1.2 Endothelial cells, cardiomyocytes co-culture system 
Two co-culture approaches were used in this study (Figure 3).   
Approach 1: HL-1 cells were seeded on the surface of 6-well plates (companion 
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plates for Falcon
®
 Transwell inserts), and ECs were seeded on the insert membrane in 
other 6 well plates without HL-1 cells. The seeding density was adjusted (around 0.5 
× 106 ) so ECs and HL-1 cells reached confluence around same time, then both cells 
were kept in serum free DMEM medium overnight. Afterwards, Falcon inserts with 
ECs were moved into companion plates which had HL-1 cells in culture. The ECs 
were stimulated with/without ET-1 (100nM).   
Approach 2: HL-1 cells were seeded on the lower part of the inserts membrane, and 
kept in a companion plate. ECs were seeded with an appropriate density (0.25 × 106, 
reach confluence in 3 days) on the top side of inserts membrane two days before HL-1 
cells reached confluence (cells on the lower part of the membrane were invisible with 
ECs seeding on the top). On the third day after seeding ECs (around 100% 
confluence), both cell culture media were changed to serum-free DMEM medium. 
After overnight incubation, ECs were stimulated with or without ET-1 (100 nM).   
 
Figure 3. Endothelial cell-cardiomyocyte co-culture system in vitro. Two different 
approaches of the co-culture system were used. Endothelial cells seeded on the insert 
membrane with cardiomyocytes seeded on the surface of the companion plate (Approach 1) 
or on the other side of the membrane (Approach 2). 
 
3.1.3 Preparation of endothelial cell conditioned medium 
After reaching confluence, ECs were gently rinsed with serum-free DMEM medium 
twice and kept in serum-free DMEM medium for overnight incubation. ECs were 
stimulated with or without ET-1 the next morning. After 24 hours, cell culture 
supernatant was collected and centrifuged at 1000 rpm for 5 min at 4℃. The 
supernatant was kept at -80°C as 500-μl aliquots (endothelial cell conditioned 
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medium, ECCM) after being flash frozen in liquid nitrogen. 
To test the effect of ECCM on fetal gene expression in HL-1 cells, ECCM aliquots 
were thawed at 37°C and added to HL-1 cells as half volume of the total cell culture 
supernatant (Figure 4A). To test the effect of different fractions of ECCM, separated 
by molecular weight, EC culture supernatant was centrifuged at 1000 rpm for 5 min, 
then further centrifuged with Vivaspin
®
 centrifugal concentrators with different 
membrane sizes (10, 30, 50, 100 kDa) at a ratio of 5 to 1 (Figure 4B). To prepare 
samples for mass spectrometry (MS) analysis, cell culture supernatant was 
concentrated with Vivaspin
®
 centrifugal concentrator of 10 kDa membrane size, at a 
ratio of about 25 to 1. The final protein concentration must be higher than 0.5 μg/μl 
(the lowest detection rang for MS) in successfully prepared samples, selected by 
Bradford protein concentration measurement.  
 
Figure 4. Preparation and experimental procedures of EC-conditioned medium (ECCM). 
A. Experimental procedure of EC-conditioned medium (with/without ET-1 pre-incubation) 
and its application on HL-1 cells. B. Experimental procedure of EC-conditioned medium 
fractions with centrifugal concentrators and its application on HL-1 cells.  
 
3.1.4 Fluid shear stress in vitro  
CI-muMECs were seeded on 60 mm cell culture dishes. Upon reaching confluence, 3% 
vinyl pyrrolidone was added to cell culture medium to increase its viscosity, and cells 
were subjected to unidirectional shear stress (≈ 30 dyn/cm2) in a cone-and-plate 
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viscometer at 37℃ with 5% CO2. After 24 hours, cell culture supernatant and the cell 
pellet was collected separately and kept at -80℃. This part was done in collaboration 
with Dr. Cordula Rumig. 
  
3.2 Biochemistry methods 
3.2.1 mRNA expression analysis  
3.2.1.1 mRNA extraction from cultured cells 
Adherent cells were rinsed with ice-cold D-PBS twice and 350 μl of RNeasy® lysis 
buffer containing 1% β-mercaptoethanol was added into each cell culture well. After 
gently shaking the whole plate for 1-2 minutes, same volume of 70% ethanol (350 μl) 
was added into each well. The mixture from each sample was transported into an 
mRNA extraction column (from RNeasy
®
 RNA extraction Kit), and extraction was 
performed according to the manufacturer’s instructions. At the last step, total RNA 
was eluted from each column with 20-30 μl RNase-free water. The concentration and 
extraction quality of RNA was measured with a NanoDrop
®
 ND-1000 
spectrophotometer. 
 
3.2.1.2 Reverse Transcription (RT) 
Reverse Transcription was performed with the Omniscript
®
 RT kit. According to the 
measured concentration, 1,000 ng RNA from each sample was diluted with 
RNase-free water to a volume of 12 μl in a Biosphere® SafeSeal Tube (1.5 ml), and 
then 8 μl of Master Mix was prepared and added into the tube according to the 
manufacturer’s instructions. The mixture was incubated at 37℃ for 60 min and 
diluted with 80 μl of water. The final concentration of cDNA in each tube was 10 
ng/μl. 
 
3.2.1.3 Quantitative real time polymerase chain reaction (qRT-PCR) 
Quantitative real time PCR was performed with a LightCycler
®
 instrument and the 
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QuantiTect
®
 SYBR
®
 Green Kit. Briefly, 5 μl cDNA (10 ng/μl) was mixed with 10 μl 
QuantiTect buffer, 1 μl forward primer (0.5 μM), 1 μl reverse primer (0.5 μM), and 3 
μl water to a total volume of 20 μl in one LightCycler® capillary. Polymerase chain 
reaction was performed according to the program listed in Table 9. To analyse the 
gene expression differences among samples in each experiment, the target gene 
expression was expressed relative to a stably expressed reference gene within the 
same samples. In this study, mouse 60S ribosomal protein L32 (mRPL32) was used as 
a reference gene. The relative target gene expression (R) was calculated according to 
Equation 1 (Michael W. Pfaffl, 2001). 
 
R =
(Etarget)
∆CPtarget (contrl−sample)
(Eref)
∆CPref (contrl−sample)
              1 
The corresponding real-time PCR efficiency (E) was calculated from the given slope 
in the LightCycler software as Equation 2. 
 
E =  10[−1/slope]                          2                                                                   
The crossing point (CP) is defined as the point at which the fluorescence rises 
appreciably above the background fluorescence.  
Tab. 9: Quantitative real time polymerase chain reaction program 
Program Temperature   Time Number of cycles 
Denaturation  95℃        15 minutes 1 
Quantification  94℃        15 seconds 
Tannealing      30 seconds 
72℃        30 seconds 
 
40-45 
Melting  95℃        15 seconds 
65℃        30 seconds 
95℃        30 seconds 
1 
Cooling  40℃        10 minutes 1 
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3.2.2 Protein expression analysis  
3.2.2.1 Total cellular protein extraction 
Cells were rinsed twice with ice-cold D-PBS and scraped off into 1 ml of ice-cold 
D-PBS. Cell suspension from each sample was collected in a 1.5 ml Eppendorf
®
 tube 
and centrifuged at 3,000 rpm for 3 min at 4℃. The cell pellets were re-suspended in 
50 μl Millipore® water after removing the supernatant. Cell suspensions were flash 
frozen in liquid nitrogen and immediately thereafter thawed at 37℃ for 5 cycles to 
break up the cell membranes and release the cellular protein. Same amount of homo-1 
buffer was added into each tube and the mixture was centrifuged at 3,000 rpm for 5 
min at 4°C. The supernatants were collected and transferred into fresh tubes and the 
protein samples were then flash frozen in liquid nitrogen and stored at -80℃. 
 
3.2.2.2 Protein concentration measurement 
Protein concentration was measured using the Bradford method. Briefly, sample 
dilutions were prepared at 1:50 or 1:100 ratios (4 μl sample in 196 μl water or 2 μl 
sample in 198 μl water). Two hundred μl Bio-Rad® Bradford Reagent was added into 
each well of a 96-well ELISA plate, 80 μl water (blank), 80 μl standard protein (5, 10, 
15, 20, 30 μg/ml) and 80 μl sample dilutions were added into each well in duplicates. 
The absorbance of each well was measured at 595 nm with a Powerwave
®
 
spectrophotometer and the concentration of the protein sample calculated by using the 
standard curve. 
 
3.2.2.3 Sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE was preformed to separate proteins generally by molecular weight. A 10% 
separating gel and 4% stacking gel was prepared according to the protocol below 
(Table 10). Equal amount of protein (5 to 15 μg) from each sample was diluted with 
water to a volume of 18 μl and then mixed with 6 μl of 4×loading buffer. The mixture 
was heated at 95℃ for 5 min and loaded into each pocket in the gel. Proteins were 
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separated by electrophoresis in running buffer at 80 V in the stacking gel for around 
30 min and then at 110 V in the separating gel for around 1.5 hours. A dual colour 
protein standard marker was loaded onto each gel to estimate the electrophoresis 
process and general distribution of the proteins. 
Tab. 10: SDS-PAGE gel preparation 
 Separating gel  
1 gel (5 ml) 
Stacking gel 
1 gel (1.5 ml) 
H2O (ml) 1.2 1.1 
Tris-HCl pH=8.8 (ml) 2 0.188 
30% Acrylamide (ml) 1.7 0.2 
10% SDS (μl) 50 15 
10% APS (μl) 50 15 
TEMED (μl) 3 1.5 
 
3.2.2.4 Western blotting 
After electrophoresis separation, proteins in the gel were transferred onto a methanol 
activated PVDF membrane in transfer buffer at 350 mA for 60-90 min (mainly 
dependent on the target protein size). Then the membrane was rinsed in 5% non-fat 
dried Blotto
®
 milk dissolved in TBS-T for 30-60 min to block unspecific binding.  
After blocking, the membrane was incubated with first antibody, dissolved in TBS-T 
at a ratio of 1:500 to 1:2000, overnight at 4℃. Subsequently, the membrane was 
rinsed in TBS-T 3 times, 5 min each, and incubated with species specific secondary 
antibody for 60-90 min at RT. Afterwards; the membrane was rinsed twice in TBS-T, 
once in TBS and then developed with Luminata
®
 Forte substrate according to the 
manufacturer’s instructions. Finally, the visualized bands were analysed using Image J 
software (NIH, Bethesda, Maryland, USA). Similar to mRNA expression analysis, 
β-actin was used as a reference gene in each experiment.  
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3.2.2.5 Enzyme Linked Immunosorbent Assay (ELISA) 
The concentration of ANP released by HL-1 cells and VEGF-C released by ECs in 
cell culture supernatants were measured by ELISA. There are four most commonly 
used ELISA types (Figure 5A). In this study, the mouse-VEGF-C ELISA kit is based 
on the standard sandwich ELISA technology. The working procedure is briefly shown 
in Figure 5B. The ANP ELISA kit is an assay based on the principle of competitive 
enzyme immunoassay, as shown in Figure 5C.  
 
Figure 5. Principle of ELISA kits used. A. Four commonly used ELISA types. B. Working 
procedure of the VEGF-C Standard Sandwich ELISA kit. A 96-well plate had been pre-coated 
with VEGF-C specific antibody. Test samples were added into the wells, incubated and 
removed. A biotinylated detection antibody specific for VEGF-C was added, incubated and 
followed by washing. Avidin-Peroxidase Conjugate was added, incubated and unbound 
conjugate was washed away. An enzymatic reaction was produced through the addition of 
TMB substrate which is converted by HRP, generating a blue: colour product that changed to 
yellow after adding acidic stop solution. The absorbance of the yellow colour read at 450 nm 
is quantitatively proportional to the amount of VEGF-C captured in the wells. C. Working 
procedure of the ANP competitive ELISA kit. The microplate was pre-coated with secondary 
antibody. After incubation with anti-ANP capture antibody, both target ANP peptide in 
samples and biotinylated ANP peptide (10 pg/ml) competitively interacted with the capture 
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antibody. Bound biotinylated ANP peptide interacted with HRP, causing the same colour 
development as described above, the intensity of which is quantitatively proportional to the 
amount of biotinylated ANP peptide-HRP complex and inversely proportional to the amount 
of ANP peptide in tested samples. (Adapted from the manufacturer’s instructions: 
Sigma-Aldrich, USA; Aviva System Biology, USA) 
 
3.2.2.6. Mass spectrometry (MS) analysis 
Preparation of ECCM samples for MS analysis was briefly introduced in Figure 4B. 
For each sample, ECCM was collected from one T25 flask, and centrifuged with a 
10-kDa centrifugal concentrator to a ratio of about 25:1. For comparison of ECCM 
contents with or without ET-1 stimulation, each pair of samples was prepared from 
two flasks of ECs with the same sub-culture passage and seeding density.   
After digestion by using trypsin as a protease, the tryptic peptides were cleaned up 
using C18 pipette tips from Merck KGaA (Damstadt, Germany). The peptide solution 
was dried under vacuum and resuspended using water containing 3% acetonitrile 
(MeCN) and 0.1% formic acid (FA).  
High-performance liquid chromatography experiments were performed using the 
UltiMate3000 system (Dionex) and a Kinetex C18 column (Phenomenex, 2-6 μm, 
100Å, i.d. 2.1 mm and length 100 mm). Water containing 5% MeCN and 0.1% FA 
was used as solvent A and MeCN containing 5% water and 0.1% FA as solvent B. A 
flow rate of 0.25 mL/min was used for each run. A multi-step gradient approach was 
used for peptide separation starting with 2% B. In 7-9 min, B was increased from 2% 
to 40%. Afterwards, B was increased to 50% in 5 min, further increased to 98% in 3 
min and kept at 98% for 8 min. The gradient was then ramped down to 2% B in 3 min. 
The HPLC system was coupled to a Q-Exactive Orbitrap mass spectrometer (Thermo 
Fisher Scientific GmbH, Bremen, Germany) using a mass range of m/z 350-1,800 and 
a mass resolution of 140,000 for full MS. The top ten peaks were fragmented using 
higher energy collisional dissociation (HCD) and a dynamic exclusion of 15 s. The 
data were analysed using Proteome Discoverer, Version 1.4. This part was done by 
Pegah Khamehgir-Silz, Justus-Liebig University, Giessen, Germany. 
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3.2.3 Cellular reactive oxygen species detection assay 
Endothelin-1 (ET-1) induced cellular reactive oxygen species in ECs were detected by 
DCF-DA. Cells seeded in 12-well plates were rinsed with warm D-PBS twice after 
reaching confluence, and incubated in D-PBS containing 5 μM DCF and 1 g/l glucose 
at 37℃ for 60 min. ET-1 (1, 10, 100 nM) was added to the ECs, and fluorescence 
was measured at 485 nm excitation/538 nm emission using a fluorescence 
spectrometer, at the time points 1 min before, and 30, 60 and 120 min after adding 
ET-1. 
 
3.2.4 Extracellular nitric oxide (NO) detection assay 
Extracellular NO levels in ECs with or without fluid shear stress or ET-1 stimulation 
was detected indirectly by measuring nitrite (NO2-) using the Griess reaction assay. 
Solution A (1% (w/v) Sulfanilamide dissolved in 1 N HCL) and solution B (0.1% 
(w/v) N-1-napthylethylenediamine dihydrochloride, NED dissolved in 1 N HCL) 
were prepared and stored at 4℃ protected from light. Nitrite standards were freshly 
prepared with dilutions of 100 μM NaOH. Both solutions were equilibrated to 
ambient temperature (15-30 min) at the beginning of each experiment. Fifty μl of each 
sample and standards were added into 96-well plates in duplicate, followed by adding 
50 μl solution A and 10 min incubation (RT, protected from light). Afterwards, 50 μl B 
was added into each well and incubated for 10 min (RT, protected from light). 
Absorbance at 520-550 nm was measured using a microplate reader within 30 min 
and nitrite concentration was calculated according to the standard curve. 
 
3.3 Immunocytochemistry 
3.3.1 Cell fixation 
Cells cultured on circular glass cover slips were rinsed with PBS and fixed in 4% PFA 
for 20 min. PFA was removed and cells were rinsed twice again with PBS. Thereafter, 
they were either processed for immunofluorescence staining or kept at 4℃. 
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3.3.2 Immunofluorescence staining 
PBS supplied with 1% BSA plus 0.3% TritonX served as a blocking buffer and 
antibody solvent. Cells were kept in blocking buffer for 30 min to reduce unspecific 
binding. Afterwards, they were incubated with primary antibody solution for 2 hours, 
followed by 3 × 5 min washing with PBS. Cells were kept in species specific 
secondary antibody solution for 1 hour and then washed 3 times with PBS for 5 min. 
These washes were performed at ambient temperature with 1-2 rpm/sec gentle 
shaking. Finally, glass cover slips were rinsed quickly with Millipore water, and put 
on one drop of Fluoroshield™ DAPI (cells face down) on clean microscope slides. 
Slides were kept in light-protected box at 4℃. 
 
3.3.3 Microscopy 
Confocal microscopy (Leica TCS SP8 laser scanning) was used to detect fluorescence 
from prepared slides (this part was done with Dr. Nina D. Ullrich and Dr. Sarawuth 
Wantha, Cardiovascular Physiology, Heidelberg University). Fluorescence density 
was calculated and analysed by the Leica Application Suite (Leica Microsystems, 
Mannheim, Germany) and Image J software (NIH, Bethesda, Maryland, USA). 
 
3.4 Statistical analysis 
All data are presented as means  standard error of the mean (SEM). Comparison 
among samples from multiple groups was performed by using one-way ANOVA 
followed by a suitable post-hoc test. Unpaired student’s t-test was applied for 
comparisons between two groups. For comparison of two groups in which the values 
in one group were reference values such as 1 or 100%, a one-sample t-test was 
performed. All statistical calculations were performed by using the InStat3 software 
package (GraphPad, San Diego, California，USA). A probability of < 0.05 was 
considered to be significantly different. Probability values are presented as *p < 0.05, 
**p < 0.01, and ***p < 0.001. Box plot figures present data distribution as median 
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line and range within 1.5 IQR (interquartile range, 25%-75%), and these were 
analysed by using OriginLab (Northampton, Massachusetts, USA). 
Results 
37 
 
4. Results 
4.1. Characterization of endothelial cells 
4.1.1 Characterization of CI-muMECs 
The CI-muMECs cell line is pulmonary and immortalized with proprietary technology.  
Experiments using immortalized human umbilical vein endothelial cells (iHUVECs) 
produced with the same technology showed satisfying performance in one study from 
our lab (Heiss et al., 2015). There was no available reference of experiments with 
CI-muMECs. In this context, basic characterization of CI-muMECs with cytokine 
stimulation was performed at the beginning of this study. 
CI-muMECs were seeded in 12-well plates and stimulated with cytokines (TNFα 
100U/ml + IFNγ 1,000U/ml) after reaching confluence. Cells were stimulated and 
harvested after 4, 8, 16 and 24 hours in the first trial. qRT-PCR analysis delineated 
peaks of VCAM-1 and MCP-1 expression around 8 hours (Figure 6A). EC-marker 
genes expression was therefore checked at 8 hours in the following experiments. As 
shown in Figure 6B, after cytokine stimulation, NOS3 mRNA expression slightly 
decreased; VCAM-1, ICAM-1 and MCP-1 mRNA expression increased significantly.  
 
Figure 6. EC-marker gene expression in CI-muMECs after cytokine stimulation on the 
mRNA level. A. VCAM-1 and MCP-1 mRNA expression in CI-muMECs after 4, 8, 16 and 
24 hours with cytokine (TNFα 100 U/ml + IFNγ 1,000 U/ml) stimulation, exemplary 
experiment. B. NOS3 (red), VCAM-1 (grey), ICAM-1 (blue) and MCP-1 (black) mRNA 
expression in CI-muMECs at 8 hours after stimulation with the same cytokines, n=4. The 
respective mRNA level in non-stimulated cells was set to 1. *p<0.05, **p<0.01 as indicated; 
n.s., not significant. 
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As shown in Figure 7A, in agreement with the mRNA expression data, VCAM-1 
protein abundance was significantly upregulated after cytokine stimulation. To 
subsequently detect NO production in CI-muMECs exposed to unidirectional fluid 
shear stress (FSS, ≈30 dyn/cm2), NOS3 protein expression was analysed by Western 
blot and formation of NO was detected indirectly by using the Griess reaction. As 
shown in Figure 7B, there was an increase in cellular NOS3 protein abundance with 
FSS, and the nitrite concentration in the supernatant (Figure 7C) was also 
significantly upregulated.   
 
Figure 7. VCAM-1 protein (A), NOS3 protein (B) expression and NO production (C) in 
CI-muMECs. Ctrl: CI-muMECs without stimulation; TNFα + IFNγ: CI-muMECs 
stimulated with TNFα 100 U/ml + IFNγ 1,000 U/ml for 24 hours; FSS: CI-muMECs exposed 
to unidirectional fluid shear stress (30 dyn/cm2) for 24 hours. VCAM-1 and eNOS protein 
expression: n=4; nitrite production: n=5. Inserts below A and B show original Western blots. 
*p<0.05, **p<0.01; n.s., not significant. 
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4.1.2 Characterization of MCECs 
The MCEC cell line has been widely used in previous researches (Barbieri and 
Weksler, 2007, He et al., 2008, Barbieri et al., 2008). Therefore, not much 
characterization experiment with cytokine stimulation was performed.  
 
4.1.2.1 ROS production in MCECs  
There have been numerous reports about endothelin-1 (ET-1) and oxidative stress in 
the cardiovascular system (Xu et al., 2004, Leurgans et al., 2016). Since ET-1 was a 
crucial molecule in our study, the effect of ET-1 on ROS production in MCECs was 
investigated. ROS production in MCECs was detected with DCF-DA. As detailed in 
the methods section, fluorescence at 485/538 nm was measured at 1 min before and 
10, 30, 60, 120 min after ET-1 (1, 10, 100 nM) stimulation. Cells with ET-1 
stimulation showed no (1 nM), rather modest (10 nM) and significant (100 nM) 
increase in fluorescence as compared to the non-stimulated control cells with time 
(Figure 8). The maximum detection period was 120 min in these experiments due to 
the occurrence of cell detachment thereafter. 
 
 
Figure 8. ROS production in MCECs upon ET-1 stimulation. Ctrl (blue): MCECs 
pre-incubated with DCF (5 µM), kept in D-PBS (plus 1 g/ml glucose) and without stimulation. 
ET-1 (1, 10, 100 nM): MCECs pre-incubated with DCF (5 µM) in D-PBS, and stimulated 
with ET-1 1 nM (red), 10 nM (green), and 100 nM (purple), n=6. 
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4.1.2.2 Von Willebrand factor (vWF) and Angiopoietin-2 (Ang2) expression in 
MCECs 
To detect vWF and Ang2 protein expression in MCECs, cells were seeded on circular 
glass cover slips in 12-well plates and prepared as detailed in the methods section.  
At baseline, both proteins showed homogeneous cellular distribution with some 
nuclear accumulation (Figure 9A). After one hour starvation, vWF and Ang2 were 
partially co-localized on the cell membrane and around-the nucleus (Figure 9B).   
 
Figure 9. vWF and Ang2 expression in MCECs. A. vWF and Ang2 expression in MCECs 
at the basal level. B. vWF and Ang2 expression in MCECs after 1 hour of starvation. 
Representative images. Fluorescence: red, vWF; green, Ang2; blue, DAPI; yellow, merge. 
Scale bar: 20 μm. 
 
4.2 Endothelin-1 (ET-1) induced fetal gene expression in HL-1 cells 
HL-1 is a cardiac myocyte cell line that can be repeatedly passaged and yet maintain 
a cardiac-specific phenotype (Claycomb et al., 1998). Despite its wide application in 
cardiovascular research, very few studies have been conducted on the effect of ET-1 
on HL-1 cells. In our study, the effects of ET-1 on ANP, BNP and β-MHC expression 
in HL-1 cells were analysed.  
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4.2.1 ET-1 induced fetal gene expression in HL-1 cells  
HL-1 cells were seeded in 12-well plates. When confluence was reached and the cells 
started to show cell contraction activity (a critical feature of cardiomyocytes), cells 
were kept in serum-free DMEM medium for overnight incubation. ET-1 (10, 30, 100 
nM) was applied to cells the next day. After 24 hours of ET-1 stimulation, total mRNA 
was extracted from the cell lysate. As shown in Figure 11, both ANP and BNP mRNA 
expression in HL-1 cells was upregulated with ET-1 stimulation. ANP expression 
increased significantly with 10 nM ET-1, and the increase was further enhanced at 
higher concentrations (30 and 100 nM). β-MHC mRNA expression was also 
upregulated reacting to ET-1 stimulation significantly.  
 
Figure 10. Fetal gene expression in HL-1 cells. Ctrl: HL-1 cells kept in serum-free DMEM 
medium without stimulation for 24 hours. ET-1: HL-1 cells kept in serum-free DMEM 
medium and stimulated with ET-1 (10, 30, 100 nM) for 24 hours. (A) ANP and BNP mRNA: 
n=5 and n=4, respectively; (B) β-MHC mRNA: n=3. *p<0.05, **p<0.01, ***p<0.001 as 
indicated. 
 
4.2.2 Endothelin-1 (ET-1) induced ANP peptide release into HL-1 cell culture 
supernatant 
HL-1 cell culture supernatants collected during the mRNA expression experiments 
were subjected to ELISA analysis, revealing that ANP peptide concentration in the 
supernatant significantly increased with ET-1 stimulation at 100 nM (Figure 11).   
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4.3 Fetal gene expression in HL-1 cells co-cultured with endothelial cells 
4.3.1 Morphology and permeability of the endothelial cell monolayer seeded on 
Falcon
®
 Transwell cell culture inserts  
MCECs were seeded on Falcon
®
 Transwell cell culture inserts (pore size: 0.4 and 3.0 
μm) with a density of 0.5 million cells/well, and kept in a companion plate with cell 
culture medium in both the upper and lower chambers. When confluence was reached, 
the inserts were rinsed briefly with D-PBS and transferred to 60-mm petri-dishes. 
WGA membrane staining was applied to MCECs with DAPI. As shown in Figure 
12A, MCECs formed a typical cobble stone monolayer on the 0.4 μm pore-size PET 
membrane. In order to check permeability of the monolayers, FITC-dextran (40 kDa) 
was added to the cell culture medium for MCECs seeded on 0.4 and 3.0 μm inserts. 
Fluorescence of the medium collected from both the upper and lower chambers after 1 
hour was determined. Compared with the control group (basal medium without 
FITC-dextran), fluorescence of the medium from the lower chamber of the 0.4 μm 
inserts essentially remained unchanged while that of the medium from the lower 
chamber of the 3.0 μm inserts was clearly increased (Figure 12B). Fluorescence of the 
medium from the upper chambers of the inserts with both pore sizes seemed quite 
similar. 
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Figure 11. ANP peptide 
concentration in HL-1 cell culture 
supernatant. Ctrl: Supernatant 
from cells without stimulation; 
ET-1: Supernatant from cells 
exposed to ET-1 (10, 100 nM) for 24 
hours, n=6, **p<0.01 as indicated. 
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Figure 12. MCECs on Falcon
®
 Transwell cell culture inserts. A. MCEC monolayer on a 0.4 
μm PET membrane. Green fluorescence: WGA; blue fluorescence: DAPI. B. Fluorescence of 
the medium from the upper and lower chambers of the inserts with 0.4 (left) and 3.0 (right) 
μm pore size. Ctrl: basal medium in companion plate without inserts and FITC-dextran (40 
kDa); Medium-up: medium from upper chamber of insert with MCECs; Medium-down: 
medium from lower chamber of insert with MCECs.  
 
4.3.2 Fetal gene expression in HL-1 cells co-cultured with endothelial cells 
4.3.2.1 ANP and BNP mRNA expression in HL-1 cells co-cultured with MCECs 
Two approaches of co-culture system were used in this study (cf. Figure 4). In both 
approaches, MCECs on inserts were stimulated with or without ET-1 (100 nM) when 
reaching confluence. After 24 hours, total mRNA in HL-1 cells was extracted and 
ANP and BNP mRNA expression analysed by qRT-PCR. In the first approach, both 
ANP and BNP mRNA expression in HL-1 cells significantly increased when 
co-cultured with MCECs, and these increases were further enhanced when the 
MCECs had been stimulated with ET-1 (Figure 13A). In the second approach, HL-1 
cell ANP mRNA expression increased significantly in a similar way as in approach 1. 
There also was an increase of BNP mRNA expression in HL-1 cells co-cultured with 
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MCECs and a further increase upon ET-1 stimulation of the MCECs, but both effects 
did not reach statistical significance (Figure 13B).  
 
Figure 13. ANP (left) and BNP (right) mRNA expression in HL-1 cells co-cultured with 
MCECs in approach-1 (A) and approach-2 (B). A. Ctrl: HL-1 cells seeded on companion 
plates without transwell inserts; MCEC: HL-1 cells seeded on companion plates with 
MCECs on transwell inserts; MCEC (ET-1): HL-1 cells seeded on companion plates with 
MCECs on transwell inserts and ET-1 (100 nM) stimulation of the MCECs for 24 hours. ANP 
mRNA: n=5; BNP mRNA: n=4. The insert on the bottom left depicts the experimental set-up. 
*p<0.05, **p<0.01, ***p<0.001 as indicated. B. Ctrl: HL-1 cells seeded on the lower side of 
transwell inserts without MCECs on the inserts; MCEC: HL-1 cells and MCECs seeded on 
two sides of the transwell insert; MCEC (ET-1): HL-1 cells and MCECs seeded on two sides 
of the transwell insert and ET-1 (100 nM) stimulation of MCECs for 24 hours. ANP mRNA: 
n=5; BNP mRNA: n=4. The insert on the bottom depicts the experimental set-up. **p<0.01, 
***p<0.001 as indicated; n.s., not significant. 
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4.3.2.2 ANP mRNA expression in HL-1 cells co-cultured with CI-muMECs 
As shown in Figure 14, there was an upregulation of ANP mRNA expression in HL-1 
cells when co-cultured with CI-muMECs, and the increase was significant with ET-1 
(100 nM) stimulation of the CI-muMECs.  
 
 
4.4 Fetal gene expression in HL-1 cells co-cultured with EC-conditioned medium 
4.4.1 ANP and BNP mRNA expression in HL-1 cells co-cultured with 
EC-conditioned medium 
HL-1 cells were kept in serum-free DMEM medium overnight until confluence was 
reached. MCEC conditioned medium with or without pre-stimulation by ET-1 of the 
MCECs was added to the HL-1 cells as half the volume of total cell culture medium 
in each group. Total mRNA in HL-1 cells was extracted after 24 hours and gene 
expression was analysed by qRT-PCR. There was a significant increase of ANP 
mRNA expression in HL-1 cells co-cultured with MCEC-conditioned medium with or 
without ET-1 pre-stimulation (Figure 15A left). BNP mRNA expression in HL-1 cells 
decreased when co-cultured with MCEC-conditioned medium while it increased in 
HL-1 cells co-cultured with the conditioned medium of MCECs that had been 
exposed to ET-1 for 24 hours before (Figure 15A right).  
To exclude the possibility of remaining biological activity of ET-1 in the conditioned 
medium of ET-1 pre-stimulated MCECs, serum-free DMEM medium containing ET-1 
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Figure 14. ANP mRNA expression in 
HL-1 cells co-cultured with CI-muMECs 
in approach-1. Ctrl: HL-1 cells seeded on 
companion plates without transwell inserts; 
CI-muMEC: HL-1 cells seeded on 
companion plates with CI-muMECs on 
transwell inserts; CI-muMEC (ET-1): 
HL-1 cells seeded on companion plates 
with CI-muMECs on transwell inserts and 
ET-1 (100 nM) stimulation of the 
CI-muMECs. n=4, **p<0.01 as indicated.  
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(100 nM) was kept at 37℃ for 24 hours and then added to the cultured HL-1 cells. 
Compared with the control group and ET-1 pre-stimulated group, ET-1 kept in 
medium at 37℃ for 24 hours did not induce an obvious increase in ANP or BNP 
mRNA expression in the HL-1 cells (Figure 15B). 
 
Figure 15. ANP and BNP mRNA expression in HL-1 cells exposed to MCEC-conditioned 
medium. A. Left: ANP mRNA; right: BNP mRNA. Ctrl: HL-1 cells kept in serum-free 
DMEM medium without stimulation; ECCM: HL-1 cells cultured with MCEC-conditioned 
medium; EC-ET1-CM: HL-1 cells cultured with ET-1 pre-stimulated MCEC-conditioned 
medium. n=5, ***p<0.001 as indicated B. Ctrl: HL-1 cells kept in serum-free DMEM 
medium; ET-1: HL-1 cells with ET-1 (100 nM) stimulation for 24 hours; ET-1 (37℃, 24h): 
HL-1 cells cultured with medium containing 100 nM ET-1 kept at 37°C for 24 hours. n=3, 
**p<0.01, ***p<0.001 as indicated; n.s., not significant; ANP and BNP mRNA levels as 
indicated 
 
4.4.2 ANP peptide release in cell culture supernatant from HL-1 cells cultured 
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medium was added. ANP peptide concentration was analysed by ELISA. There was 
an obvious upregulation of ANP concentration in the supernatant from HL-1 cells 
cultured with MCEC-conditioned medium which was significantly enhanced further 
upon pre-stimulation of the MCECs with ET-1 (Figure 16 left). Similar findings were 
obtained with the conditioned medium of CI-muMECs with ANP concentrations in 
the supernatant of the HL-1 cells rising significantly especially when the CI-muMECs 
had been pre-stimulated with ET-1 (Figure 16 right).  
 
Figure 16. ANP peptide concentration in the supernatant of cultured HL-1 cells. Ctrl: 
Supernatant from HL-1 cells cultured with serum-free DMEM medium; ECCM: Supernatant 
from HL-1 cells cultured with EC-conditioned medium; ECCM(ET-1): Supernatant from 
HL-1 cells cultured with the conditioned medium of ECs pre-stimulated with ET-1 (100 nM) 
for 24 hours. n=5, *p<0.05, **p<0.01 as indicated 
 
4.5 Analysis of EC-conditioned medium 
4.5.1 Rough fractionation of the EC-conditioned medium according to molecular 
mass 
To classify the contents in the EC-conditioned medium affecting HL-1 cell gene 
expression by molecular weight (MW), MCEC-conditioned medium was concentrated 
with filtration through Vivaspin
®
 centrifugal concentrators (membrane exclusion pore 
size: 10, 30 and 50 kDa). Compared with basal conditioned medium, fractionated 
medium with contents exceeding a MW of 10, 30 or 50 kDa maintained the effect of 
inducing ANP mRNA expression in the HL-1 cells. Fractions containing contents with 
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smaller MW did not show this effect (Figure 17).  
 
Figure 17. ANP mRNA expression in HL-1 cells with fractionated MCEC-conditioned 
medium. Filtration membrane pore size: 10, 30 and 50 kDa; Concentrator capacity: 6 ml; 
Spin Speed: 3000 ×g, 10-15 min; Fraction containing contents with MW larger than 
membrane pore size, concentration ratio: around 5 to 1; Fraction containing contents with 
MW smaller than membrane pore size. Representative experiment (right) with the principle 
illustrated on the left. 
 
4.5.2 SDS-PAGE analysis of EC-conditioned medium 
Concentrated (10 kDa Vivaspin
®
 centrifugal concentrator) MCEC-conditioned 
medium with and without prior ET-1 stimulation was separated by SDS-PAGE 
followed by staining of the gel with Coomassie blue resulted in concentration of a 
band with a MW of around 60 kDa (Figure 18A). On a second SDS-PAGE, human 
recombinant angiopoietin-2 (MW: 57 kDa, Hr-Ang2) was loaded followed by Western 
blot analysis with a specific anti-Ang2 antibody, yielding a band on the blot with a 
very similar MW than the Coomassie blue-stained band on the SDS-PAGE (Figure 
20B). To further confirm whether the contents of the bands from the EC-conditioned 
medium mainly consisted of Angiopoietin-2, control, ECCM and ET-1-stimulated 
ECCM were blotted as well, yielding visible bands of a similar size also with the 
mouse ECCM (Figure 18B). 
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Figure 18. SDS-PAGE analysis of MCEC-conditioned medium. A. Coomassie blue 
staining of SDS-PAGE gel, protein loading: 10 μg. B. Western blot PVDF membrane stained 
with anti-Ang2 antibody, protein loading: 10 μg. Medium control: serum-free DMEM 
medium; ECCM: MCEC-conditioned medium (concentrated); EC-ET1-CM: medium of 
MCECs prior stimulated with 100 nM ET-1 for 24 hours (concentrated); Hr-Ang2: Human 
recombinant angiopoietin-2, 5 µg; FCS: foetal bovine serum; HUVEC: human umbilical vein 
endothelial cells. Representative experiments.  
 
4.6 Angiopoietin-2 and endothelin-1 co-effects on fetal gene expression in HL-1 
cells 
4.6.1 ANP mRNA expression in HL-1 cells  
Next, expression of the Ang2 receptor Tie1/2 in HL-1 cells was analysed by qRT-PCR. 
The crossing point for Tie1 receptor cDNA in the PCR program was larger than 33, 
which is considered below the detectable range. Moreover, there was a significant 
decrease of Tie2 receptor mRNA expression in HL-1 cells co-cultured with MCECs 
compared with that at the basal level (Figure 19A). Ang2 was added to HL-1 cells at 
different concentrations (0.1 to 10 ng/ml), with or without ET-1 (100 nM), and cells 
were harvested after 24 hours for further analysis. As shown in Figure 19B, there was 
a decrease of ANP mRNA expression in HL-1 cells exposed to Ang2 at concentrations 
higher than 1 ng/ml. There was an upregulation of ET-1 (100 nM) induced ANP 
mRNA expression in the presence of 1 ng/ml Ang2 while a decrease was seen with 10 
ng/ml Ang2. 
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Figure 19. The effect of Angiopoietin-2 on ANP mRNA expression in HL-1 cells. A. Tie2 
receptor mRNA expression in HL-1 cells, +: HL-1 cells co-cultured with MCECs in 
approach-1, n=3, *p<0.05. B. ANP mRNA expression in HL-1 cells in the absence or 
presence of Ang2 (as indicated) with or without co-stimulation with ET-1 (100 nM). 
Representative experiment.   
 
4.6.2 Effects of Angiopoietin-2 on endothelin-1-stimulated ANP mRNA 
expression in HL-1 cells 
To further explore the effect of Ang2 on ET-1 induced ANP mRNA expression in 
HL-1 cells, Ang2 (1 ng/ml) was applied to cells 30 min prior to ET-1 (10, 30, 100 nM) 
stimulation, and cells were harvested 24 hours later. ANP mRNA expression in HL-1 
cells increased with increasing ET-1 concentrations. Pre-incubation with 1 ng/ml 
Ang2 provoked a significant enhancement of ET-1-induced ANP expression at 10 nM. 
Stimulation with higher concentrations of ET-1 (30, 100 nM) revealed a slight but 
insignificant decrease in ANP mRNA expression following pre-incubation with 1 
ng/ml Ang2 (Figure 20A). Higher concentrations of Ang2 (10 ng/ml) significantly 
decreased ET-1-induced ANP mRNA expression in HL-1 cells (Figure 20B).  
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Figure 20. Angiopoietin-2 affects Endothelin-1–induced ANP mRNA expression in HL-1 
cells. A. ANP mRNA expression in HL-1 cells pre-incubated with Ang2 (1 ng/ml) and 
stimulated with ET-1 (10, 30, 100 nM) afterwards, n=5, **p<0.01 as indicated; n.s., not 
significant. B. ANP mRNA in HL-1 cells pre-incubated with Ang2 (3, 10 ng/ml) and 
stimulated with ET-1 (100 nM) afterwards, n=3, *p<0.05as indicated; n.s., not significant.  
 
4.6.3 ANP peptide concentration in cell culture supernatant from HL-1 cells 
cultured with Angiopoietin-2 and Endothelin-1 
Cell culture supernatant from HL-1 cells stimulated with ET-1 (10, 100 nM) with or 
without Ang2 (1 ng/ml) pre-incubation was collected 24 hours after stimulation. 
Consistent with the increased ANP expression at the mRNA level, Ang2 (1 ng/ml) 
pre-incubation had a pronounced but not yet significant augmenting effect on ANP 
peptide release from HL-1 cells induced by 10 nM ET-1 (Figure 21).  
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Figure 21. ANP peptide concentration in the supernatant of cultured HL-1 cells. Ctrl: 
Supernatant from HL-1 cells cultured in serum-free DMEM medium, without stimulation. 
ET-1: Supernatant from HL-1 cells cultured in serum-free DMEM medium with or without 
Ang2 (1 ng/ml) exposure 30 min prior to ET-1 (10, 100 nM) stimulation for 24 hours. n=6; 
n.s., not significant. 
 
4.7 The role of nuclear factor of activated T-cells (NFAT) in endothelial 
cell-cardiomyocyte interaction 
4.7.1 NFAT activity inhibition in endothelial cell-cardiomyocyte interaction 
To investigate whether the calcineurin-NFAT pathway plays a role in EC-conditioned 
medium (ECCM) induced ANP expression in HL-1 cells, FK506, a calcineurin 
activity inhibitor (Sieber and Baumgrass, 2009), was applied to HL-1 cells 30 min 
before adding the EC-conditioned medium. FK506 (100 nM) pre-incubation did not 
show much effect on ECCM-induced ANP mRNA expression in HL cells. There was 
a clear but just not significant decrease of ET-1-enhanced ECCM-mediated ANP 
mRNA expression by FK506 (Figure 22). 
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Figure 22. ANP mRNA expression in HL-1 cells cultured with MCEC-conditioned 
medium with and without NFAT inhibition. Ctrl: HL-1 cells cultured in serum-free 
DMEM medium; ECCM: HL-1 cells cultured with MCEC-conditioned medium; 
FK+ECCM: HL-1 cells cultured with MCEC-conditioned medium and pre-incubation with 
FK506 (100 nM); EC-ET1-CM: HL-1 cells cultured with ET-1 (100 nM) pre-stimulated 
MCEC-conditioned medium; FK+EC-ET1-CM: HL-1 cells cultured with ET-1 (100 nM) 
pre-stimulated MCEC-conditioned medium and FK506 pre-treatment. n=3; n.s., not 
significant.  
 
4.7.2 Vascular endothelial growth factor C (VEGF-C) release in EC-conditioned 
medium 
The release of VEGF-C, a calcineurin-NFAT pathway related ligand, by endothelial 
cells, was analysed by ELISA. MCECs and CI-muMECs were kept in serum-free 
DMEM medium upon reaching confluence. After overnight starvation, ET-1 (100 nM) 
was applied to the cells and conditioned medium collected after 4 and 24 hours with 
and without stimulation by ET-.1. VEGFR2 and VEGFR3 mRNA expression were 
detected by qRT-PCR. There was some decrease in receptor expression in HL-1 cells 
stimulated with ET-1 (10, 100 nM) (Figure 23A). In the MCEC culture supernatant 
there was a time-dependent accumulation of VEGF-C peptide that was not affected by 
ET-1 (100 nM) stimulation (Figure 23B). In the conditioned medium of CI-muMECs, 
VEGF-C peptide was not detectable. 
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Figure 23. VEGF receptor expression in HL-1 cells and VEGFC concentration in the 
conditioned medium of MCECs. A. VEGFR2 and VEGFR3 mRNA expression in HL-1 
cells with or without Ang2 (1 ng/ml) and ET-1 (10, 100 nM) stimulation, n=2. B. VEGF-C 
peptide concentrations in the supernatant of MCECs after 4 and 24 hours exposure to ET-1 
(100 nM), n=5; *p<0.05 as indicated; n.s., not significant.  
 
4.8 Qualitative mass spectrometry analysis of EC-conditioned medium 
4.8.1 Gene ontology annotation of proteins detected in EC-conditioned medium 
by mass spectrometry 
Conditioned medium from MCECs and CI-muMECs was concentrated with 10 kDa 
Vivaspin
®
 centrifugal concentrators. From each sample, 5 ml of conditioned medium 
was concentrated to around 100 µl, with a final protein concentration corresponding 
to 0.5-1.0 µg/µl. For each group, 3 samples from independent experiments were 
prepared. Mass spectrometry results were analysed with DAVID Bioinformatics 
Resources 6.8 (NIH, US). Distinctively presented proteins identified in the control 
and ET-1 (100 nM) stimulated groups were categorized with Gene Ontology (GO) 
annotation. Proteins were grouped into three well-established GO categories, known 
as cellular components, biological process and molecular function.  
There were 265 proteins identified in MCEC-conditioned medium at baseline of 
which 33 proteins were distinctively present, mainly associated with the extracellular 
exosome and proteolysis (Figure 24A). After ET-1 stimulation 347 proteins were 
identified of which 73 were distinctively presented, mostly related with protein 
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folding and protein binding (Figure 24B). In CI-muMEC-conditioned medium, there 
were 538 proteins identified at baseline of which 68 were distinctively presented, 
mainly associated with transport and nucleotide binding (Figure 24C). After ET-1 
stimulation, 472 proteins were identified in the supernatant of which 68 were 
distinctively present, mostly involved in RNA binding and splicing (Figure 24D). 
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Figure 24. GO annotation of distinctively present proteins in each group of MCEC and 
CI-muMEC supernatants with or without ET-1 (100 nM) stimulation. A. Proteins 
distinctively present in MCEC supernatant at baseline. B. Proteins distinctively present in 
MCEC supernatant after ET-1 stimulation. C. Proteins distinctively present in CI-muMEC 
supernatant at baseline. D. Proteins distinctively present in CI-muMEC supernatant after ET-1 
stimulation. Average percentages of n=3 individual experiments for each group. 
 
4.8.2 Gene functional classification of differently released proteins in 
EC-conditioned medium 
Functional clusters of distinctively present proteins in EC-conditioned medium were 
analysed with DAVID Bioinformatics Resources 6.8 (Table 11). Cluster 1 and 2 were 
formed from the most abundant proteins identified in the secretome of MCECs at 
baseline and following ET-1 (100 nM) stimulation, cluster 3 from those present in the 
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secretome of quiescent CI-muMECs, and cluster 4 of the most abundant proteins in 
the secretome of ET-1 (100 nM) stimulated CI-muMECs. 
Tab.11: Functional clusters of distinctively present proteins identified in the different 
EC secretomes 
Cluster-1 Uniprot 
Accession 
Protein 
 P21107 tropomyosin 3, gamma (Tpm3) 
 
P47753 
capping protein (actin filament) muscle Z-line, alpha 
1 (Capza1) 
 Q6IRU2 tropomyosin 4 (Tpm4)  
 P58771 tropomyosin 1, alpha (Tpm1) 
 
Cluster-2 Uniprot 
Accession 
Protein 
 Q8BGZ7 keratin 75 (Krt75)  
 Q9Z2T6 keratin 85 (Krt85)  
 P02535 keratin 10 (Krt10)  
 Q9ERE2 keratin 81 (Krt81)  
 Q61897 keratin 33B (Krt33b)  
 Q497I4 keratin 35 (Krt35)  
 
Cluster-3 Uniprot 
Accession 
Protein 
 O35737 heterogeneous nuclear ribonucleoprotein H1 
(Hnrnph1)  
 P49312 heterogeneous nuclear ribonucleoprotein A1 
(Hnrnpa1)  
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 Q8VIJ6 splicing factor proline/glutamine rich 
(polypyrimidine tract binding protein associated) 
(Sfpq)  
 P29341 poly(A) binding protein, cytoplasmic 1 (Pabpc1)  
 
Cluster-4 Uniprot 
Accession 
Protein 
 O35737 heterogeneous nuclear ribonucleoprotein H1 
(Hnrnph1)  
 P49312 heterogeneous nuclear ribonucleoprotein A1 
(Hnrnpa1)  
 Q8VIJ6 splicing factor proline/glutamine rich 
(polypyrimidine tract binding protein associated) 
(Sfpq)  
 P29341 poly(A) binding protein, cytoplasmic 1 (Pabpc1)  
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5. Discussion 
5.1 Characterization of endothelial cells  
5.1.1 Characterization of CI-muMECs 
VCAM-1 and ICAM-1 are well-known cell surface proteins expressed in endothelial 
cells, playing important roles during inflammation and endothelial cell-leukocyte 
interaction. Expression of both proteins had been indicated in pulmonary 
microvascular endothelial cells (Xue et al., 2017, Sievert et al., 2015). MCP-1 is one 
of the key chemokines that play an important role in the diapedesis of monocytes and 
their differentiation  to macrophages (Deshmane et al., 2009). NO, a critical 
cardiovascular signalling molecule, can be generated by three different isoforms of 
the enzyme NO synthase (NOS). The endothelial NOS (NOS3 or eNOS), is mostly 
expressed in endothelial cells (Forstermann and Sessa, 2012). Nitrite is a central 
homeostatic molecule in NO biology and serves as an important signalling molecule 
in its own right (Bryan et al., 2005). Nitrite and nitrate levels in blood have been 
widely used as an index of endothelial NO synthase activity  (Bryan and Grisham, 
2007, Kleinbongard et al., 2003).  
TNFα and IFNγ are cytokines that play an important role in endothelial cell activation 
and dysfunction. Previous work indicated that expression of adhesion molecules such 
as VCAM-1, ICAM-1 and E-selectin or chemokines by microvascular endothelial 
cells is upregulated upon exposure to these cytokines (Zhang, 2008, Pober and Sessa, 
2007). NO production was also reported to be correlated with the effect of these 
cytokines (Dinarello, 2007). In our study, VCAM-1, ICAM-1 and MCP-1 mRNA 
expression in CI-muMECs increased significantly with cytokine stimulation and there 
was a slight decrease of NOS3 mRNA expression. These results were in accordance 
with the known effects of these cytokines on macrovascular endothelial cells. 
Furthermore, there was a significant increase of VCAM-1 abundance on CI-muMECs 
24 hours after cytokines stimulation.  
Under physiological conditions, endothelial cells are exposed to mechanical forces 
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caused by the flowing blood and the beating heart (Davies, 1995). Among these forces, 
shear stress appears to be a particularly important hemodynamic force. It stimulates 
the release of vasoactive substances, namely that of NO, and regulates gene 
expression, cell metabolism, and cell morphology (Davies, 1995, Traub and Berk, 
1998). In our study, NOS3 protein expression by CI-muMECs cultured in the 
presence of fluid shear stress increased compared to the basal level, and there was a 
significantly higher concentration of nitrite, as an indirect measure of NO release in 
the supernatant. Combined with the decrease of NOS3 mRNA levels following 
cytokine stimulation, NOS3 activity and expression as well as their response to 
pro-inflammatory cytokines seem to be regulated normally in these conditionally 
immortalised murine microvascular ECs.  
 
5.1.2 Characterization of MCECs 
When exposed to endothelin-1, MCECs revealed an increased production of ROS, 
presumably mainly peroxides,ROS and oxidative stress are important features of 
cardiovascular diseases including atherosclerosis, hypertension, and congestive heart 
failure (Sugamura and Keaney, 2011). Endothelium-derived ROS may also contribute 
to cardiac remodelling (Zhang and Shah, 2014). The enhanced ROS signal detected in 
MCECs upon ET-1 stimulation suggested such a possible effect also on the HL-1 cells 
they have been co-cultured with. In this context, it would be interesting to be able to 
detect the ROS signal for more than 120 min. Keeping cells in proper condition for 
longer time during detection would be a critical point. Optimization of solvent of 
DCF-DA during incubation and fluorescence detection period might improve cellular 
performance in future experiments. 
Angiopoietin-2 has been extensively investigated in angiogenesis and inflammation. 
Angiogenesis and inflammation are common companion conditions in the process of 
cardiac hypertrophy (Shiojima et al., 2005); however little is known about Ang2 
expression and its regulation in cardiac microvascular ECs. Von Willebrand factor is 
an adhesive and multimeric glycoprotein extensively studied during haemostasis 
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(Peyvandi et al., 2011). Since the first report about its expression by cardiac 
microvascular endothelial cells in the 1990s (Aird et al., 1997, Edelberg et al., 1998), 
only few studies have been conducted regarding its regulation in the heart. In the 
MCECs, both Ang2 and vWF were highly abundant with homogeneous distribution in 
the cytoplasm. After one hour of starvation, there was an obvious accumulation of 
both proteins on the cell membrane as compared to quiescent cells, indicating that 
both proteins may share a similar route of transportation in the cell upon serum 
removal stress. MCECs, on the other hand, did not express appreciable amounts of 
NOS3 or reacted to FSS by increasing the formation/release of NO.   
 
5.2 Endothelin-1 induced fetal gene expression in HL-1 cells 
Previous studies demonstrated that ET-1 plasma levels correlate with the development 
of cardiac hypertrophy (Liu et al., 2017, Xu et al., 2017). In fact, ET-1 has been 
widely used to induce cardiac remodelling (Archer et al., 2017, Viero et al., 2016) or 
as a stimulus to study hypertrophy-related pathways (Seidlmayer et al., 2016, Irvine et 
al., 2013). Little was known about the effect of ET-1 on HL-1 cells. ANP protein 
abundance in HL-1 cells was markedly enhanced 48 hours post ET-1 stimulation 
(Hong et al., 2011). In our experiments, ANP mRNA expression significantly 
increased upon exposure to 10 nM ET-1, and the increment became greater with 
higher concentrations. Also BNP mRNA expression increased upon ET-1 stimulation 
but not as avidly as that of ANP. Although ANP and BNP are closely related 
natriuretic peptide hormones, clinical trials (Grandi et al., 2004, Rubattu et al., 2006, 
Uusimaa et al., 2004) suggest that their plasma levels correlate with different 
parameters such as diastolic dysfunction and ventricular hypertrophy. In our hands, 
ANP and BNP expression in HL-1 cells reacted differently to ET-1 stimulation, a 
finding compatible with previous results by another group (Sergeeva and Christoffels, 
2013). Also upregulated was β-MHC expression in response to ET-1 stimulation, 
providing further evidence to support a reprogramming of gene expression in the 
HL-1 cells.   
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5.3 Fetal gene expression in HL-1 cells co-cultured with endothelial cells 
5.3.1 HL-1 cell-endothelial cell co-culture system 
Co-culturing cells, namely on a Transwell insert within a companion plate, is a 
well-established model to investigate cell-cell interactions in vitro (Sattayaprasert et 
al., 2016, Heiss et al., 2015). As described in the methods section, two co-culture 
approaches were used in this study. In both approaches, pores in the Transwell 
membrane allowed molecules released from endothelial cells, which were seeded on 
top of the insert, to diffuse to the other side of the membrane and further into the 
bottom chamber. Moreover, in the approach in which HL-1 cells were seeded on the 
lower side of membrane, the pores in the membrane provided the possibility for a 
direct physical contact of the two cell types on each side of the membrane.  
From experience in our laboratory, human umbilical vein endothelial cells seeded on 
the PET membrane form a tight monolayer upon reaching confluence. In the present 
co-culture experiments, MCECs seeded on the Transwell inserts with 0.4 μm and 3.0 
μm pore size also formed a cobblestone-like monolayer upon reaching confluence, 
which was in line with basic endothelial cell characteristics. 
The vascular endothelium is permeable for molecules from 0.1 nm to 11.5 nm in 
diameter. Two transport mechanisms were defined for solute/ion influx into the vessel 
wall through the EC monolayer: The transport of macromolecules larger than 3 nm, 
such as albumin, IgG, and others, via the transcellular pathway, also referred to as 
transcytosis or vesicular transport.
 
Molecules smaller than 3 nm, such as glucose, 
water, and ions, can pass through inter-endothelial junctions via the paracellular 
pathway (Sukriti et al., 2014). In our study, permeability of the MCEC monolayer on 
the Transwell inserts was evaluated with FITC-labelled dextran of 40 kDa which has 
an estimated molecule diameter of 4.5 µm. As expected, monolayers on the 3.0-μm 
pore size membrane showed much higher permeability compared with that on the 
0.4-μm pore size membrane. Considering the molecule diameter of the FITC-labelled 
dextran used, the rather high permeability of the MCEC monolayer on the 3.0-μm 
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pore size membrane may have been due to impaired inter-endothelial junctions. In 
order to have a reasonably tight monolayer, therefore, only the 0.4-μm pore size 
membrane was used in further experiments.  
 
5.3.2 ANP and BNP mRNA expression in HL-1 cells co-cultured with endothelial 
cells 
As delineated in the introduction section, microvascular endothelial cells and 
cardiomyocytes interact through multiple pathways under physiological and 
pathophysiological conditions. The secretome of microvascular cardiac ECs 
contribute largely to the maintenance of proper cardiomyocyte function (Coppiello et 
al., 2015, Parodi and Kuhn, 2014, Paulus and Tschope, 2013). In our study, after 
co-culturing with MCECs for 24 hours, ANP and BNP expression in HL-1 cells was 
upregulated in both co-culture settings, suggesting that a component within the 
MCEC secretome induces or reinforces induction of the fetal gene program in the 
cardiomyocyte cell line. 
With ET-1 stimulation of MCECs, ANP and BNP expression in HL-1 cells was 
markedly upregulated compared to untreated MCECs. ET-1 stimulation apparently 
induced a change in the MCEC secretome that further enhanced transcription of the 
ANP and BNP genes in the HL-1 cells. A similar effect was seen when instead of 
MCECs the supernatant of ET-1-stimulated CI-muMECs was employed.  
A study by Nolan et al. (Nolan et al., 2013) suggests that there is tissue/organ-specific 
heterogeneity of microvascular endothelial cells with respect toclusters of 
transcription factors, angiocrine growth factors, adhesion molecules, and chemokines 
that are expressed in unique combinations by such ECs of different organs. In fact, the 
MCECs which are of cardiac origin displayed a different gene expression pattern than 
the CI-muMECs which are derived from the lungs. Nonetheless does the 
ET-1-stimulated secretome of both microvascular endothelial cell types contain a 
similar humoral factor or factors that induces or reinforces the fetal gene program in 
Discussion 
64 
 
HL-1 cells. 
 
5.4 Fetal gene expression in HL-1 cells co-cultured with endothelial cell 
conditioned medium  
As discussed above, the endothelial cell monolayer on the Transwell inserts with 
0.4-μm pore size showed very little permeability for FITC-labelled dextran. ET-1 has 
a much smaller molecular mass (2.5 kDa) than the 40 kDa dextran preparation used 
and hence a smaller size (1.9 nm as compared to 4.5 nm). To exclude the possible 
effect of a leak of ET-1 from the upper to the lower chamber through the Transwell 
filter insert, ET-1  at a concentration of 100 nM dissolved in serum-free DMEM 
medium was kept at 37℃ for 24 hours to facilitate its decomposition. When compared 
to freshly added ET-1 at the same concentration, the serum-free DMEM had very little 
if any effect on ANP and BNP expression by the HL-1 cells, suggesting that it is not 
any excess ET-1 leaking through the Transwell filter that caused the effect of the 
EC-conditioned medium on HL-1 cell gene expression.. As a consequence, next the 
nature of the factor or factors in the EC-conditioned medium was investigated 
assuming that it probably is a polypeptide or protein. 
 
5.5 Analysis of EC-conditioned medium  
5.5.1 EC-conditioned medium fractionation by molecular weight 
Application of centrifugal concentrators has been reported to be a practical method to 
concentrate and fractionate cell culture supernatant by molecular weight (Saha et al., 
1992, Zimmermann et al., 2011). First, the EC-conditioned medium was fractionated 
by concentrators with exclusion sizes of 10, 30 and 50 kDa. ANP mRNA expression 
in HL-1 cells increased significantly with fractions containing polypeptides or 
proteins larger than 10, 30 or 50 kDa. The effect exerted by the fractionated 
EC-conditioned medium was much larger than that induced by the unfractionated 
EC-conditioned medium, which may have been due to the concentration 
(approximately 5 times) of the medium during the filtration step. The flow through 
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fractions did not affect ANP mRNA expression in the HL-1 cells. As suggested by the 
technical service from the supplier (Sartorius), the pore size of the filters could 
provide a rough estimate of the molecular weight of the contents separated by the 
filter, but cannot serve as a distinct cut-off. Nonetheless, these results strongly 
indicated that the polypeptide factor in the MCEC-conditioned medium that induces 
ANP mRNA expression in the HL-1 cells should be equal to or larger than 50kDa. 
  
5.5.2 SDS-PAGE analysis of EC-conditioned medium 
This fractionation of the EC-conditioned medium also offered the possibility to have 
enough protein in the concentrated fraction for SDS-PAGE analysis. Coomassie blue 
staining delineated several bands from 10 to up to 100 kDa but there was no 
appreciable difference in staining intensity between bands detected in the fractionated 
EC-conditioned medium and the fractionated conditioned medium of MCECs 
pre-incubated with ET-1, suggesting that the method may not be sensitive enough.  
Among proteins ≥50 kDa known to be released by microvascular cells, angiopoietin-2 
plasma levels have been reported to correlate with cardiac function (Lukasz et al., 
2013, Poss et al., 2015). Therefore, human recombinant Ang2 (Hr-Ang2) was 
subjected to SDS-PAGE followed by Western blot analysis, and produced a band with 
a similar size than a murine protein of about 60 kDa detected in 
theMCEC-conditioned medium , insinuating that this may in fact contain Ang2. 
Therefore, the potential role of MCEC-derived Ang2 in inducing or reinforcing ANP 
and BNP expression by HL-1 cells was investigated further. 
 
5.6 Angiopoietin-2 and endothelin-1 co-effect on fetal gene expression in HL-1 
cells 
Despite the extensively studied role of Ang2 in angiogenesis, very little is known 
about its effect on cardiomyocytes. In one study (Greulich et al., 2012) 
cardiomyocytes treated with secretory products from epicardial adipose tissue of 
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patients with type 2 diabetes mellitus that was enriched in Ang2 caused reductions in 
sarcomere shortening, cytosolic calcium fluxes, and expression of sarcoplasmic 
endoplasmic reticulum ATPase 2a. 
Since there were no reports about Ang2 receptor expression in HL-1 cells, we 
measured these ourselves. While Tie1 mRNA levels were below the detection limit of 
the qRT-PCR, Tie2 mRNA expression was significantly decreased in HL-1 cells 
co-cultured with MCECs, indicating that a secreted protein such as Ang2 may have 
activated the HL-1 cell Tie2 receptors. Exposure of the HL-1 cells to authentic Ang2 
caused a concentration-dependent decrease in ANP expression while ET-1-induced 
ANP expression was augmented by low concentrations of Ang2 (1 ng/ml) but 
inhibited by high concentrations of Ang2 (10 ng/ml). Tie2 receptor activation in 
endothelial cells is linked to pro-inflammatory signalling pathways (Milam and Parikh, 
2015), while the Ang2-dependent signal transduction in cardiomyocytes is not yet 
clear. Moreover, Ang2 plasma concentration has been reported to be associated with 
cardiovascular disease (Nadar et al., 2005, Tabit et al., 2016). Due to these varying, 
concentration-dependent effects of authentic Ang2 on basal or ET-1-stimulated 
MCEC-mediated induction of the fetal gene program in the HL-1 cells, it is difficult 
to conclude that (i) Ang2 is in fact the humoral factor present in the 
MCEC-conditioned medium and (ii) how this is effect is brought about by Ang2 in the 
cardiomyocyte cell line. Further experiments are required to elucidate this point. In 
this regard, a neutralising anti-Ang2 antibody did not significantly attenuate the 
stimulatory effect of the EC-conditioned medium with or without ET-1 
pre-stimulation on ANP expression by the HL-1 cells. 
 
5.7 The role of NFAT in endothelial cell-cardiomyocyte interaction 
NFAT is an extensively studied transcription factor family in cardiac remodelling 
(Corban et al., 2017, Bakthavatsalam et al., 2014) that is generally activated upon 
dephosphorylation in the cytoplasm by the calcium-dependent phosphatase 
calcineurin. In our study, a calcineurin inhibitor, FK506, had no effect on the 
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MCEC-conditioned medium-dependent upregulation of ANP mRNA in the HL-1 cells 
but downregulated the additional effect of the conditioned medium from MCECs 
pre-stimulated with ET-1. Increased NFAT activity is mainly involved in 
pathophysiological cardiac remodelling rather than physiological remodelling induced, 
e.g. by endurance sports (Clerk et al., 2007). In this context, induction of the fetal 
gene program in the HL-1 cells by the conditioned medium of ET-1-stimulated 
endothelial cells might be achieved through different cellular signalling mechanisms 
than that mediated by the conditioned medium of quiescent endothelial cells. 
Activation of NFAT through the calcium-calcineurin pathway may be responsible in 
part for this difference.  
VEGF-C is a calcineurin-NFAT pathway related ligand known to be released by 
endothelial cells, the concentration of which in the conditioned medium of quiescent 
or ET-1-pre-stimulated MCECs did not differ. Although there was a ET-1-mediated 
decrease in expression of the VEGF receptors 2 and 3 that are both targeted by 
VEGF-C, this finding essentially excludes VEGF-C, despite a fitting molecular mass, 
as the humoral factor which mediates the prominent stimulatory effect of the 
conditioned medium of ET-1-pre-stimulated ECs on HL-1 cell expression of fetal 
genes such ANP, BNP or β-MHC. On the other hand, it does not exclude the 
possibility that VEGF-C like Ang2 contributes to ANP and BNP mRNA expression in 
the HL-1 cells induced by the conditioned medium from quiescent microvascular 
ECs. 
 
5.8 Mass spectrometry analysis of EC-conditioned medium 
5.8.1 Gene ontology annotation of proteins detected in EC-conditioned medium 
by mass spectrometry 
In an alternative approach to identify candidate polypeptides present in the 
conditioned medium of the ECs, mass spectrometry analysis was used which provides 
this possibility (Hu et al., 2016). Gene ontology (GO) annotation allows for the 
interpretation of the potential involvement of a specific protein within a group of 
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proteins with similar biological function (Gene Ontology, 2015). Thus analysed, the 
majority of proteins detected in the EC-conditioned medium could be classified into 
three well established GO categories: biological process(es), cellular component and 
molecular function. Moreover, proteins released from quiescent and ET-1-stimulated 
MCECs are frequently found in exosomes. While the most abundant proteins in the 
secretome of quiescent MCECs are associated with proteolysis, those in the secretome 
of ET-1-pre-stimulated MCECs are involved in protein folding and binding. Proteins 
detected in the secretome of quiescent or ET-1-stimulated CI-muMECs represented 
mainly cytoplasmic or exosomal proteins.  While the former are mostly related with 
transport and cell adhesion, the latter are associated mainly with RNA processing and 
splicing.  
Exosomes are extracellular vesicles containing key mediators of intercellular 
communication. Previous studies demonstrated that cardiac progenitor cells, HUVECs, 
and mesenchymal stem cells derived exosomes modulate cardiac function (Barile et 
al., 2017, Wang et al., 2017a). The results of our mass spectrometry analysis suggest 
that the secretome of the microvascular ECs contains exosomal proteins and thus 
perhaps whole exosomes. In addition, they support the notion of a cellular 
heterogeneity among microvascular ECs from different tissue/organ origin. 
 
5.8.2 Gene functional classification of distinctively presented proteins in 
EC-conditioned medium 
The DAVID Gene Functional Classification tool uses an agglomeration algorithm to 
condense a list of genes or associated biological terms into organized classes of 
related genes or biology, called biological modules (Huang et al., 2007). In our study, 
it served as a tool to classify functionally related proteins into biological modules for 
better interpretation of the microvascular EC secretome. Clusters (groups of proteins) 
characteristic for the conditioned medium of quiescent and ET-1-stimulated 
CI-muMECs comprised different members of heterogeneous nuclear 
ribonucleoproteins (hnRNPs), i.e. RNA-protein complexes present in the nucleus 
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during gene transcription and post-transcriptional modification of pre-mRNA. There 
is no evidence for a direct link between hnRNPs and pathophysiological cardiac 
remodelling (hypertrophic cardiomyopathy). However, one member of the hnRNP 
family, HnRNPA2B1, has been shown to be in charge of micro-RNA loading into 
exosomes (Villarroya-Beltri et al., 2013). Two other hnRNP family members, 
hnRNPA1 and hnRNPC, can also bind to exosomal miRNAs, suggesting that they 
might be candidates for miRNA sorting as well (Zhang et al., 2015).   
MicroRNAs continue to spark interest in the process of cardiac hypertrophy. Thus, 
miR-22, a cardiac- and skeletal muscle-enriched microRNA, was found to be 
upregulated during myocyte differentiation and cardiomyocyte hypertrophy, and 
overexpression of miR-22 was sufficient to induce cardiomyocyte hypertrophy 
(Huang et al., 2013). Cardiac-specific overexpression of miR-206 in mice also 
induced hypertrophy but protected the heart from ischemia/reperfusion injury, 
whereas suppression of miR-206 exacerbated ischemia/reperfusion injury and 
prevented pressure overload-induced cardiac hypertrophy (Yang et al., 2015). 
Combined with the GO cellular component annotation, our findings may support the 
concept that exosomes containing functional RNAs play important role in endothelial 
cell-cardiomyocyte interaction. Furthermore, the effect of hnRNPs on RNA sorting 
and transport might link them to the process of cardiac hypertrophy, and make them a 
potentially interesting target for future manipulation of microvascular 
EC-cardiomyocyte interaction. 
 
5.8.3 Pathway analysis of distinctively presented proteins in EC-conditioned 
medium 
The DAVID Pathway analysis function also provided the possibility to connect a list 
of proteins with up-to-date intercellular and extracellular signalling pathways from 
established pathway databases (such as KEGG). There were numerous pathways 
comprising proteins from our input list. In consideration of cell-cell communication, 
pathways containing ligand-receptor interaction(s) would be particularly interesting. 
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In this context, two components of complement C1, the complex that initiates the 
classical pathway of complement activation, C1/r (90 kDa) and C1/s (80 kDa), could 
be potential mediators of the stimulatory effect of EC-conditioned medium on HL-1 
cell fetal gene expression. One study showed that overexpression of C1/r and C1/s 
induces cardiac hypertrophy in mice (Yang et al., 2007). In our study, both C1/r and 
C1/s were present in the secretome of quiescent MCECs which is at variance with 
some of the previous findings. However, they whet the appetite for further 
investigations in this direction.
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6. Summary  
The anatomic arrangement of microvascular endothelial cells and cardiomyocytes in 
vivo enables close interactions among these cells. In our in vitro co-culture system, 
ANP and BNP mRNA expression in cardiomyocytes and subsequent ANP release 
were significantly upregulated when co-cultured with endothelial cells or exposed to 
endothelial cell-conditioned medium. Combined with previous results indicating a 
crucial role for ANP and BNP in cardiac homeostasis, our finding provide further 
evidence that paracrine signalling by cardiac microvascular endothelial cells 
modulates cardiomyocyte function.   
Endothelin-1 (ET-1) activation of endothelial cells remarkably enhanced their 
paracrine effects on cardiomyocyte gene expression in our study, suggesting for the 
first time that ET-1 stimulation of endothelial cells affects expression of fetal genes 
such as ANP and BNP in adult cardiomyocytes through paracrine signalling. Elevated 
plasma levels of ET-1 are observed during hypertension and cardiac hypertrophy, and 
microvascular activation and inflammation have been reported to accompany cardiac 
hypertrophy. The present results further confirm the importance of an intact 
microvascular homeostasis for the pathogenesis of such complex cardiac disease 
processes and might provide a basis for future therapeutic strategies targeting 
microvascular endothelial cell-cardiomyocyte interaction during cardiac hypertrophy. 
Such a strategy may comprise inhibition of the calcineurin-NFAT pathway in the 
cardiomyocytes which herein selectively inhibited the stimulatory effect on 
cardiomyocyte fetal gene expression by the conditioned medium derived from 
ET-1-pre-stimulated endothelial cells. 
The importance of keeping the balance between angiogenesis and cardiomyocyte 
growth during cardiac hypertrophy has frequently been addressed in the past. In our 
study, angiopoietin-2 (Ang2) alone or in combination with exogenous ET-1 affected 
cardiomyocyte ANP expression and release in a concentration-dependant manner. In 
consideration of elevated plasma levels of Ang2 in patients with acute or chronic heart 
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failure, these results may spur further studies on the role of Ang2 in cardiac 
remodelling processes.  
Mass spectrometry analysis of endothelial cell-conditioned media revealed qualitative 
differences in the release of proteins from endothelial cells with and without ET-1 
stimulation. Gene ontology annotation of the detected proteins points towards a role 
for exosomes and proteins involved in RNA folding in endothelial cell-cardiomyocyte 
crosstalk. Based on previous findings of a role for micro-RNAs in this type of 
cell-to-cell communication, endothelial cell-derived exosomal micro-RNAs may not 
only mediate part of the biological effects of the microvascular endothelial 
cell-conditioned medium described herein but also provide a basis to targeting such 
potentially maladaptive endothelial cell-cardiomyocyte interactions in the future.  
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Zusammenfassung 
Mikrovaskuläre Endothelzellen und Kardiomyozyten sind zwei Zelltypen, welche in 
vivo in anatomisch in direktem Kontakt zueinander stehen, was nahelegt, dass diese 
Zellen miteinander interagieren. In unseren in vitro Co-kultur Experimenten haben 
wir in Kardiomyozyten eine signifikante Zunahme der ANP und BNP mRNA 
Expression, sowie der darauf folgenden ANP Sekretion feststellen können, wenn 
Kardiomyozyten entweder zusammen mit Endothelzellen kultiviert wurden, oder mit 
Endothelzell-konditioniertem Medium behandelt wurden. In Verbindung mit früheren 
Ergebnissen, welche auf eine entscheidende Rolle für ANP und BNP in der Erhaltung 
der kardiale Homöostase hindeuten, liefern unsere Ergebnisse weitere Beweise, dass 
parakrine Signalwege der kardialen mikrovaskulären Endothelzellen die Funktion von 
Kardiomyozyten modellieren. 
Gabe von Endothelin-1, welches Endothelzellen aktiviert, konnte in unseren 
Versuchen den parakrin vermittelten Effekt auf die Genexpression der 
Kardiomyozyten verstärken, was Endothelin-1 Stimulation als bisher unbekannten 
Faktor in der parakrinen Signalübertragung zu adulten Kardiomyozyten über die 
Expression fötaler Gene wie ANP und BNP, nahelegt. Erhöhte Endothelin-1 
Plasmakonzentrationen wurden bereits in der Vergangenheit bei Hypertonie und 
ventrikuläre Hypertrophie festgestellt. Gleichsam wurden mikrovaskuläre Aktivierung 
und Entzündung zusammen mit diesen Krankheitsbildern gefunden. Die gezeigten 
Ergebnisse bestätigen wie wichtig die mikrovaskuläre Homöostase in der Pathogenese 
dieser komplexen kardialen Erkrankungen ist und könnte die Entwicklung neuer 
therapeutischer Ansätze ermöglichen, welche die mikrovaskulären Endothelzellen und 
ihre Interaktion mit Kardiomyozyten ins Ziel fassen. Ein möglicher Ansatz könnte die 
Inhibition des Calcineurin-NFAT Signalwegs sein. Diese Inhibition unterbindet die 
Aktivierung der Expression fötaler Gene in Kardiomyozyten, nachdem diese mit 
konditioniertem Medium von Endothelin-1-aktivierten Endothelzellen behandelt 
wurden. 
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Schon in zahlreichen Studien wurde die Balance zwischen Angiogenese und 
Kardiomyozytenwachstum im Zusammenhang mit Hypertrophie untersucht. In 
unserem Experiment hat Angiopoitin-2 alleine oder in Kombination mit exogenem 
Endothelin-1 einen konzentrationsabhängigen Effekt auf die 
Kardiomyozytenexpression und Sekretion von ANP. Da die Angiopoietin-2 
Konzentration im Plasma von Patienten mit akuter oder chronischer Herzinsuffizienz 
erhöht ist, könnten unsere Ergebnisse weitere Studien anregen, welche die Rolle von 
Angiopoietin-2 im kardialen Remodelling-Prozess behandeln.  
Die massenspektrometrische Analyse von Zellkulturmedium, in welchem 
Endothelzellen kultiviert wurden, zeigen deutliche qualitative Unterschiede im 
Proteingehalt, wenn die Endothelzellen zuvor mit Endnothelin-1 stimuliert wurden im 
Vergleich zu nicht stimulierten Endothelzellen. Anschließend durchgeführte 
genontologische Untersuchungen der detektierten Proteine deuten darauf hin, dass 
diese wichtig für Bildung von Exosomen, RNA-Faltung und 
Endothelzell-Kardiomyozyten-Interaktionen sind. 
Es ist bekannt, das Mikro-RNA in dieser Art der Zell-zu-Zell Kommunikation 
involviert sind. Es ist daher möglich, dass exosomale Mikro-RNA aus Endothelzellen 
nicht nur den hier Beschriebenen Effekt haben, sondern ein potentielles Ziel darstellen 
um künftig fehlerhafte Endothelzell-zu-Kardiomyozyten-Kommunikation zu 
behandeln.  
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